A	O
p56lck	B-protein
-independent	O
pathway	O
of	O
CD2	B-protein
signaling	O
involves	O
Jun	B-protein
kinase	I-protein
.	O

The	O
p56	B-protein
Src	I-protein
family	I-protein
non-receptor	I-protein
tyrosine	I-protein
kinase	I-protein
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
T	O
lymphocyte	O
differentiation	O
and	O
activation	O
.	O

Hence	O
in	O
the	O
absence	O
of	O
p56	B-protein
,	O
T	B-protein
cell	I-protein
receptor	I-protein
triggered	O
activation	O
does	O
not	O
occur	O
.	O

We	O
now	O
provide	O
evidence	O
for	O
a	O
CD2	B-protein
-based	O
signaling	O
pathway	O
which	O
,	O
in	O
contrast	O
to	O
that	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
,	O
is	O
independent	O
of	O
p56	B-protein
.	O

CD2	B-protein
-mediated	O
interleukin-2	B-protein
production	O
occurs	O
via	O
activation	O
of	O
Jun	B-protein
kinase	I-protein
in	O
cell	O
lines	O
lacking	O
p56	B-protein
.	O

Jun	B-protein
kinase	I-protein
then	O
facilitates	O
the	O
binding	O
of	O
c-Jun/c-Fos	B-protein
heterodimers	I-protein
to	O
the	O
AP-1	B-DNA
consensus	I-DNA
site	I-DNA
and	O
the	O
subsequent	O
transcriptional	O
activity	O
of	O
the	O
interleukin-2	B-DNA
promoter	I-DNA
.	O

These	O
data	O
elucidate	O
differences	O
between	O
TCR	B-protein
and	O
CD2	B-protein
signaling	O
pathways	O
in	O
the	O
same	O
T	B-cell_type
cells	I-cell_type
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

273	NULL
,	NULL
No	NULL
.	NULL

37	NULL
,	NULL
Issue	NULL
of	NULL
September	NULL
11	NULL
,	NULL
pp	NULL
.	NULL

24249-24257	NULL
,	NULL
1998	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
A	NULL
p56	NULL
``	NULL
-independent	NULL
Pathway	NULL
of	NULL
CD2	NULL
Signaling	NULL
Involves	NULL
Jun	NULL
Kinase*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
March	NULL
5	NULL
,	NULL
1998	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
June	NULL
5	NULL
,	NULL
1998	NULL
)	NULL
Raute	NULL
Sunder-Plassmannt	NULL
and	NULL
Ellis	NULL
L.	NULL
Reinherz	NULL
$	NULL
§	NULL
From	NULL
the	NULL
Laboratory	NULL
of	NULL
Immunobiology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
and	NULL
Department	NULL
of	NULL
Medicine	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
The	NULL
p56	NULL
``	NULL
**	NULL
Sre	NULL
family	NULL
non-receptor	NULL
tyrosine	NULL
kinase	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
T	NULL
lymphocyte	NULL
differentiation	NULL
and	NULL
activation	NULL
.	NULL

Hence	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
triggered	NULL
activation	NULL
does	NULL
not	NULL
occur	NULL
.	NULL

We	NULL
now	NULL
provide	NULL
evidence	NULL
for	NULL
a	NULL
CD2-based	NULL
signaling	NULL
pathway	NULL
which	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
that	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
,	NULL
is	NULL
independent	NULL
of	NULL
p56	NULL
``	NULL
.	NULL

CD2-mediated	NULL
interleukin-2	NULL
production	NULL
occurs	NULL
via	NULL
activation	NULL
of	NULL
Jun	NULL
kinase	NULL
in	NULL
cell	NULL
lines	NULL
lacking	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

Jun	NULL
kinase	NULL
then	NULL
facilitates	NULL
the	NULL
binding	NULL
of	NULL
c-Jun/c-Fos	NULL
heterodimers	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
and	NULL
the	NULL
subsequent	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
.	NULL

These	NULL
data	NULL
elucidate	NULL
differences	NULL
between	NULL
TCR	NULL
and	NULL
CD2	NULL
signaling	NULL
pathways	NULL
in	NULL
the	NULL
same	NULL
T	NULL
cells	NULL
.	NULL

CD2	NULL
is	NULL
a	NULL
cell	NULL
surface	NULL
glycoprotein	NULL
which	NULL
is	NULL
expressed	NULL
on	NULL
immature	NULL
thymocytes	NULL
and	NULL
on	NULL
mature	NULL
T	NULL
cells	NULL
and	NULL
NK	NULL
cells	NULL
(	NULL
1-3	NULL
)	NULL
.	NULL

The	NULL
ligand	NULL
for	NULL
human	NULL
CD2	NULL
is	NULL
CD58	NULL
(	NULL
LFA-3	NULL
)	NULL
,	NULL
a	NULL
ubiquitously	NULL
expressed	NULL
cell	NULL
surface	NULL
protein	NULL
found	NULL
on	NULL
many	NULL
cell	NULL
types	NULL
including	NULL
antigen	NULL
presenting	NULL
cells	NULL
(	NULL
4	NULL
,	NULL
5	NULL
)	NULL
.	NULL

Unlike	NULL
integrins	NULL
such	NULL
as	NULL
CD11a/CD18	NULL
(	NULL
LFA-1	NULL
)	NULL
,	NULL
the	NULL
adhesion	NULL
between	NULL
CD2	NULL
and	NULL
CD58	NULL
is	NULL
not	NULL
dependent	NULL
on	NULL
TCR	NULL
triggering	NULL
(	NULL
6	NULL
,	NULL
7	NULL
)	NULL
.	NULL

Rather	NULL
,	NULL
the	NULL
CD2-CD58	NULL
interaction	NULL
between	NULL
T	NULL
cells	NULL
and	NULL
their	NULL
cognate	NULL
partners	NULL
facilitates	NULL
the	NULL
T	NULL
cell	NULL
recognition	NULL
process	NULL
and	NULL
subsequent	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
8-10	NULL
)	NULL
.	NULL

Cross-linking	NULL
of	NULL
CD2	NULL
molecules	NULL
by	NULL
specific	NULL
pairs	NULL
of	NULL
mAbs	NULL
recognizing	NULL
distinct	NULL
epitopes	NULL
on	NULL
human	NULL
CD2	NULL
initiates	NULL
a	NULL
signaling	NULL
cascade	NULL
which	NULL
leads	NULL
to	NULL
T	NULL
cell	NULL
cytokine	NULL
production	NULL
,	NULL
prolifer-ation	NULL
,	NULL
and	NULL
cytolytic	NULL
activity	NULL
(	NULL
11-13	NULL
)	NULL
.	NULL

For	NULL
optimal	NULL
mAb-mediated	NULL
activation	NULL
two	NULL
antibody	NULL
specificities	NULL
are	NULL
needed	NULL
,	NULL
one	NULL
directed	NULL
against	NULL
conventional	NULL
CD2	NULL
epitopes	NULL
and	NULL
the	NULL
second	NULL
against	NULL
an	NULL
activation-associated	NULL
epitope	NULL
of	NULL
CD2	NULL
,	NULL
termed	NULL
CD2R	NULL
.	NULL

The	NULL
CD2R	NULL
epitope	NULL
has	NULL
recently	NULL
been	NULL
mapped	NULL
to	NULL
the	NULL
flexible	NULL
linker	NULL
region	NULL
between	NULL
the	NULL
two	NULL
extracellular	NULL
domains	NULL
of	NULL
CD2	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Its	NULL
appearance	NULL
coincides	NULL
with	NULL
reorientation	NULL
of	NULL
the	NULL
adhesion	NULL
domain	NULL
(	NULL
D1	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
membrane	NULL
proximal	NULL
domain	NULL
(	NULL
D2	NULL
)	NULL
of	NULL
the	NULL
CD2	NULL
extracellular	NULL
segment	NULL
.	NULL

Such	NULL
domain	NULL
reorientation	NULL
occurs	NULL
upon	NULL
*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grants	NULL
AI21226	NULL
and	NULL
Al19807	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
17834	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

7	NULL
Supported	NULL
by	NULL
Erwin	NULL
Schrodinger	NULL
Auslandsstipendium	NULL
JO1086-MED	NULL
from	NULL
the	NULL
Fonds	NULL
zur	NULL
Forderung	NULL
der	NULL
Wissenschaftlichen	NULL
Forschung	NULL
,	NULL
Vienna	NULL
,	NULL
Austria	NULL
.	NULL

§	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Laboratory	NULL
of	NULL
Immunobiology	NULL
,	NULL
Dana-Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
44	NULL
Binney	NULL
St.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
617-682-8412	NULL
;	NULL
Fax	NULL
:	NULL
617-682-8851	NULL
;	NULL
E-mail	NULL
:	NULL
ellis	NULL
_reinherz	NULL
@	NULL
dfci.harvard.edu	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
TCR	NULL
,	NULL
T	NULL
cell	NULL
receptor	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
MAPK	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
;	NULL
PLC	NULL
,	NULL
phospholipase	NULL
C	NULL
;	NULL
PMSF	NULL
,	NULL
phenylmethylsulfony	NULL
]	NULL
l	NULL
fluoride	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
18-ace-tate	NULL
;	NULL
DTT	NULL
,	NULL
dithiothreitol	NULL
;	NULL
GST	NULL
,	NULL
glutathione	NULL
S-transferase	NULL
;	NULL
EMSA	NULL
,	NULL
elec-trophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
CD58	NULL
binding	NULL
to	NULL
CD2	NULL
and	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
CD2	NULL
interaction	NULL
with	NULL
CD58	NULL
regulates	NULL
the	NULL
responsiveness	NULL
of	NULL
activated	NULL
human	NULL
T	NULL
cells	NULL
to	NULL
IL-12	NULL
(	NULL
15	NULL
,	NULL
16	NULL
)	NULL
.	NULL

Hence	NULL
,	NULL
both	NULL
IL-12-stimulated	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
interfer-on-y	NULL
production	NULL
are	NULL
markedly	NULL
augmented	NULL
by	NULL
CD2	NULL
ligation	NULL
.	NULL

Finally	NULL
,	NULL
some	NULL
studies	NULL
have	NULL
uncovered	NULL
a	NULL
unique	NULL
role	NULL
for	NULL
CD2	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
anergy	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
anergized	NULL
alloreactive	NULL
T	NULL
cells	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
specific	NULL
alloantigen	NULL
in	NULL
conjunction	NULL
with	NULL
CD2-CD58	NULL
co-receptor	NULL
ligation	NULL
reverses	NULL
the	NULL
an-ergic	NULL
state	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
identical	NULL
allostimulation	NULL
but	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
CD2-CD58	NULL
co-ligation	NULL
on	NULL
T	NULL
cells	NULL
and	NULL
allostimulators	NULL
,	NULL
respectively	NULL
,	NULL
fails	NULL
to	NULL
restore	NULL
responsiveness	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Signaling	NULL
through	NULL
CD2	NULL
is	NULL
dependent	NULL
on	NULL
its	NULL
cytoplasmic	NULL
domain	NULL
(	NULL
8	NULL
,	NULL
18-20	NULL
)	NULL
.	NULL

Comparison	NULL
of	NULL
CD2	NULL
from	NULL
various	NULL
species	NULL
shows	NULL
the	NULL
highest	NULL
homology	NULL
occurring	NULL
in	NULL
this	NULL
segment	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

While	NULL
the	NULL
cytoplasmic	NULL
domain	NULL
has	NULL
no	NULL
intrinsic	NULL
protein-tyrosine	NULL
kinase	NULL
activity	NULL
and	NULL
no	NULL
tyrosine	NULL
residues	NULL
which	NULL
might	NULL
serve	NULL
as	NULL
docking	NULL
sites	NULL
for	NULL
SH2	NULL
domains	NULL
upon	NULL
phosphorylation	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

23	NULL
and	NULL
24	NULL
)	NULL
,	NULL
stimulation	NULL
via	NULL
CD2	NULL
leads	NULL
to	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
several	NULL
intracellular	NULL
proteins	NULL
(	NULL
25-27	NULL
)	NULL
.	NULL

For	NULL
these	NULL
activation	NULL
events	NULL
CD2	NULL
signaling	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
CD34	NULL
chain	NULL
in	NULL
T	NULL
cells	NULL
(	NULL
27-31	NULL
)	NULL
or	NULL
FceeRIy	NULL
in	NULL
CD16	NULL
expressing	NULL
NK	NULL
cells	NULL
(	NULL
82	NULL
)	NULL
.	NULL

The	NULL
CD2	NULL
tail	NULL
contains	NULL
several	NULL
proline-rich	NULL
regions	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Two	NULL
of	NULL
these	NULL
(	NULL
PPPGHR	NULL
)	NULL
are	NULL
known	NULL
to	NULL
be	NULL
important	NULL
in	NULL
inducing	NULL
IL-2	NULL
production	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Related	NULL
proline-rich	NULL
sequences	NULL
bind	NULL
to	NULL
SH3	NULL
domains	NULL
of	NULL
non-receptor	NULL
protein-tyrosine	NULL
kinases	NULL
of	NULL
the	NULL
Src	NULL
family	NULL
(	NULL
23	NULL
)	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
SH3	NULL
domain	NULL
of	NULL
p56	NULL
``	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
rat	NULL
CD2	NULL
cytoplasmic	NULL
tail	NULL
at	NULL
least	NULL
in	NULL
vitro	NULL
(	NULL
34	NULL
)	NULL
.	NULL

Peptides	NULL
corresponding	NULL
to	NULL
residues	NULL
269-270	NULL
and	NULL
200-310	NULL
(	NULL
according	NULL
to	NULL
the	NULL
human	NULL
CD2	NULL
numbers	NULL
)	NULL
bind	NULL
to	NULL
p56	NULL
'	NULL
``	NULL
*-GST	NULL
fusion	NULL
proteins	NULL
(	NULL
34	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
intracellular	NULL
colocalization	NULL
exper-iments	NULL
,	NULL
however	NULL
,	NULL
suggest	NULL
,	NULL
that	NULL
p59	NULL
``	NULL
rather	NULL
than	NULL
p56	NULL
``	NULL
*	NULL
has	NULL
a	NULL
predominant	NULL
association	NULL
with	NULL
CD2	NULL
(	NULL
35	NULL
)	NULL
,	NULL
perhaps	NULL
by	NULL
binding	NULL
through	NULL
the	NULL
p59	NULL
``	NULL
SH3	NULL
domain	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
protein	NULL
tyrosine	NULL
kinases	NULL
is	NULL
one	NULL
of	NULL
the	NULL
proximal	NULL
steps	NULL
in	NULL
signaling	NULL
cascades	NULL
which	NULL
ultimately	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cell	NULL
effector	NULL
function	NULL
.	NULL

For	NULL
p56	NULL
``	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
this	NULL
kinase	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
Ras/Raf/	NULL
MAPK	NULL
pathway	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
function	NULL
of	NULL
MAPK	NULL
is	NULL
mani-fold	NULL
.	NULL

Several	NULL
studies	NULL
reported	NULL
that	NULL
MAPK	NULL
can	NULL
phosphorylate	NULL
and	NULL
activate	NULL
the	NULL
transcription	NULL
factors	NULL
ELK	NULL
,	NULL
Jun	NULL
,	NULL
and	NULL
Stat-1	NULL
and	NULL
thereby	NULL
participates	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
gene	NULL
expression	NULL
(	NULL
37	NULL
)	NULL
.	NULL

A	NULL
different	NULL
pathway	NULL
leading	NULL
to	NULL
Jun	NULL
activation	NULL
is	NULL
the	NULL
Rac/JNK	NULL
pathway	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
Pyk2	NULL
tyrosine	NULL
kinase	NULL
has	NULL
been	NULL
described	NULL
,	NULL
shown	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
JNK	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
has	NULL
been	NULL
linked	NULL
to	NULL
TCR	NULL
signaling	NULL
via	NULL
p59	NULL
``	NULL
(	NULL
40	NULL
)	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
have	NULL
begun	NULL
to	NULL
dissect	NULL
the	NULL
differences	NULL
in	NULL
TCR-	NULL
and	NULL
CD2-based	NULL
signaling	NULL
pathways	NULL
.	NULL

Since	NULL
p56	NULL
``	NULL
*	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
most	NULL
important	NULL
at	NULL
a	NULL
proximal	NULL
step	NULL
in	NULL
CD3	NULL
signaling	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
role	NULL
p56	NULL
``	NULL
plays	NULL
in	NULL
CD2	NULL
signaling	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
have	NULL
employed	NULL
the	NULL
Jurkat	NULL
variant	NULL
JCaM1.6s	NULL
24249	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
24250	NULL
which	NULL
lacks	NULL
functional	NULL
p56	NULL
``	NULL
**	NULL
and	NULL
is	NULL
unable	NULL
to	NULL
transmit	NULL
TCR	NULL
signals	NULL
leading	NULL
to	NULL
IL-2	NULL
production	NULL
.	NULL

We	NULL
here	NULL
report	NULL
that	NULL
although	NULL
the	NULL
TCR	NULL
pathway	NULL
is	NULL
not	NULL
functional	NULL
in	NULL
JCaM1.6s	NULL
,	NULL
these	NULL
cells	NULL
can	NULL
be	NULL
induced	NULL
to	NULL
produce	NULL
IL-2	NULL
by	NULL
stimulation	NULL
via	NULL
CD2	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
present	NULL
evidence	NULL
for	NULL
a	NULL
p56	NULL
``	NULL
*-independent	NULL
CD2	NULL
signal	NULL
transduction	NULL
pathway	NULL
which	NULL
uses	NULL
Pyk2	NULL
and	NULL
JNK	NULL
and	NULL
leads	NULL
to	NULL
the	NULL
binding	NULL
of	NULL
c-Jun/c-Fos	NULL
heterodimers	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
,	NULL
important	NULL
for	NULL
initiation	NULL
of	NULL
IL-2	NULL
transcription	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Cell	NULL
Lines	NULL
and	NULL
Antibodies	NULL
Monoclonal	NULL
antibodies	NULL
(	NULL
mAbs	NULL
)	NULL
:	NULL
anti-T11	NULL
;	NULL
,	NULL
anti-T1l1	NULL
,	NULL
,	NULL
and	NULL
anti-Tl1l	NULL
,	NULL
recognizing	NULL
different	NULL
epitopes	NULL
of	NULL
human	NULL
CD2	NULL
(	NULL
11	NULL
)	NULL
and	NULL
the	NULL
anti-human	NULL
CD3e	NULL
mAbs	NULL
2AD2A2	NULL
and	NULL
RW28C8	NULL
(	NULL
41	NULL
)	NULL
were	NULL
developed	NULL
in	NULL
our	NULL
laboratory	NULL
at	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
.	NULL

4G10	NULL
(	NULL
anti-phos-photyrosine	NULL
,	NULL
IgG2b	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Tom	NULL
Roberts	NULL
(	NULL
Dana	NULL
Farber	NULL
Cancer	NULL
Institute	NULL
)	NULL
.	NULL

Rabbit	NULL
antisera	NULL
against	NULL
ZAPT70	NULL
,	NULL
p56**	NULL
,	NULL
and	NULL
Pyk2	NULL
were	NULL
kind	NULL
gifts	NULL
from	NULL
J.	NULL
Bolen	NULL
(	NULL
DNAX	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
A.	NULL
Veillette	NULL
(	NULL
McGill	NULL
Cancer	NULL
Center	NULL
,	NULL
Montreal	NULL
,	NULL
Quebec	NULL
,	NULL
Canada	NULL
)	NULL
,	NULL
and	NULL
J.	NULL
Schlessinger	NULL
(	NULL
New	NULL
York	NULL
University	NULL
Medical	NULL
Center	NULL
,	NULL
New	NULL
York	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

Antibodies	NULL
against	NULL
PLC-y1	NULL
were	NULL
obtained	NULL
from	NULL
Upstate	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
,	NULL
and	NULL
rabbit	NULL
antisera	NULL
against	NULL
p59	NULL
``	NULL
,	NULL
Erk1/MAPK	NULL
,	NULL
JNK	NULL
,	NULL
c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
JunD	NULL
,	NULL
c-Fos	NULL
,	NULL
Fral	NULL
,	NULL
Fra2	NULL
,	NULL
and	NULL
FosB	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
.	NULL

Rabbit	NULL
antiserum	NULL
against	NULL
pMAPK	NULL
was	NULL
obtained	NULL
from	NULL
New	NULL
England	NULL
Biolabs	NULL
,	NULL
Beverly	NULL
,	NULL
MA	NULL
.	NULL

Cell	NULL
Lines-The	NULL
Jurkat	NULL
variant	NULL
,	NULL
JCaM1.6	NULL
,	NULL
that	NULL
lacks	NULL
p56	NULL
``	NULL
*	NULL
(	NULL
42	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
ATCC	NULL
(	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
sorted	NULL
for	NULL
high	NULL
CD2	NULL
and	NULL
CD3	NULL
expression	NULL
(	NULL
JCaM1.6s	NULL
)	NULL
and	NULL
further	NULL
sorted	NULL
for	NULL
those	NULL
cells	NULL
which	NULL
show	NULL
a	NULL
fast	NULL
and	NULL
high	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
levels	NULL
following	NULL
CD2	NULL
stimulation	NULL
(	NULL
JCaM1.6s.93	NULL
)	NULL
.	NULL

Both	NULL
JCaM1.6s	NULL
and	NULL
JCaM1.6s.88	NULL
were	NULL
analyzed	NULL
for	NULL
p56	NULL
``	NULL
**	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
activity	NULL
and	NULL
p56	NULL
``	NULL
*	NULL
was	NULL
found	NULL
to	NULL
be	NULL
not	NULL
enzymatically	NULL
active	NULL
.	NULL

J77	NULL
is	NULL
a	NULL
CD2°	NULL
``	NULL
CD3	NULL
``	NULL
``	NULL
CD8	NULL
``	NULL
°®	NULL
subclone	NULL
of	NULL
the	NULL
Jurkat	NULL
cell	NULL
line	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Ca	NULL
``	NULL
*	NULL
Assay	NULL
Ca	NULL
``	NULL
*	NULL
assay	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
(	NULL
48	NULL
)	NULL
.	NULL

Increase	NULL
in	NULL
intracellular	NULL
free	NULL
Ca	NULL
``	NULL
*	NULL
in	NULL
Indo-1	NULL
(	NULL
Molecular	NULL
Probes	NULL
Inc.	NULL
,	NULL
Eugene	NULL
,	NULL
OR	NULL
)	NULL
loaded	NULL
cells	NULL
was	NULL
induced	NULL
by	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-Tll	NULL
,	NULL
and	NULL
anti-T11	NULL
,	NULL
(	NULL
1:100	NULL
)	NULL
or	NULL
20	NULL
ug/ml	NULL
biotinylated	NULL
RW28CS	NULL
alone	NULL
or	NULL
by	NULL
further	NULL
cross-linking	NULL
with	NULL
100	NULL
pg/ml	NULL
avidin	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

Maximal	NULL
Ca**	NULL
influx	NULL
was	NULL
induced	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
10	NULL
ug/ml	NULL
4-bromo-calcium	NULL
ionophore	NULL
A23187	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

The	NULL
analysis	NULL
was	NULL
performed	NULL
on	NULL
an	NULL
EPICS	NULL
V	NULL
cell	NULL
sorter	NULL
(	NULL
Coulter	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
Tyrosine	NULL
Phosphorylation	NULL
Immunoprecipitation	NULL
was	NULL
performed	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
43	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
min	NULL
at	NULL
87	NULL
°C	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-T11	NULL
,	NULL
and	NULL
anti-T1l1	NULL
,	NULL
(	NULL
1:100	NULL
)	NULL
or	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
1:100	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
ice-cold	NULL
TBS	NULL
(	NULL
50	NULL
mm	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
)	NULL
,	NULL
resuspended	NULL
in	NULL
lysis	NULL
buffer	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
;	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
in	NULL
TBS	NULL
,	NULL
10	NULL
ug/ml	NULL
leupeptin	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
0.2	NULL
TIU/ml	NULL
aprotinin	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
(	NULL
Fisher	NULL
Scientific	NULL
,	NULL
Fair	NULL
Lawn	NULL
,	NULL
NJ	NULL
)	NULL
,	NULL
5	NULL
mM	NULL
Na	NULL
,	NULL
H	NULL
,	NULL
P,0	NULL
,	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
and	NULL
5	NULL
mM	NULL
sodium	NULL
fluoride	NULL
(	NULL
Fisher	NULL
)	NULL
or	NULL
25	NULL
mM	NULL
B-glycerophosphate	NULL
(	NULL
Sigma	NULL
)	NULL
)	NULL
and	NULL
rotated	NULL
for	NULL
80	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
18,000	NULL
x	NULL
g	NULL
for	NULL
5	NULL
min	NULL
.	NULL

Proteins	NULL
were	NULL
immunoprecipitated	NULL
from	NULL
1	NULL
ml	NULL
of	NULL
postnuclear	NULL
lysate	NULL
with	NULL
10	NULL
ul	NULL
of	NULL
GammaBind	NULL
Plus-Sepharose	NULL
(	NULL
Pharmacia	NULL
Biotech	NULL
Inc.	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
preincubated	NULL
with	NULL
the	NULL
respective	NULL
Abs	NULL
.	NULL

Beads	NULL
bound	NULL
immune	NULL
complexes	NULL
were	NULL
washed	NULL
with	NULL
lysis	NULL
buffer	NULL
and	NULL
TBS	NULL
and	NULL
were	NULL
eluted	NULL
by	NULL
boiling	NULL
in	NULL
SDS	NULL
(	NULL
Laemmli	NULL
)	NULL
sample	NULL
buffer	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
SDS-PAGE	NULL
and	NULL
Western	NULL
blotted	NULL
as	NULL
described	NULL
below	NULL
.	NULL

In	NULL
Vitro	NULL
Kinase	NULL
Assay-Lysis	NULL
of	NULL
cells	NULL
(	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells/ml	NULL
)	NULL
and	NULL
immunoprecipitation	NULL
was	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
above	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
lysis	NULL
buffer	NULL
and	NULL
kinase	NULL
buffer	NULL
(	NULL
100	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
MnCl	NULL
,	NULL
5	NULL
my	NULL
MgCl	NULL
,	NULL
,	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
the	NULL
beads	NULL
bound	NULL
immune	NULL
complexes	NULL
were	NULL
resuspended	NULL
in	NULL
50	NULL
pl	NULL
of	NULL
kinase	NULL
buffer	NULL
containing	NULL
2	NULL
uM	NULL
ATP	NULL
and	NULL
were	NULL
incubated	NULL
with	NULL
10	NULL
uCi	NULL
of	NULL
[	NULL
y-	NULL
``	NULL
PIATP	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Kinase	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
addition	NULL
of	NULL
ice-cold	NULL
lysis	NULL
buffer	NULL
containing	NULL
20	NULL
mM	NULL
EDTA	NULL
.	NULL

After	NULL
washing	NULL
3	NULL
times	NULL
with	NULL
lysis	NULL
buffer/EDTA	NULL
and	NULL
once	NULL
with	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
the	NULL
phosphorylated	NULL
proteins	NULL
were	NULL
eluted	NULL
by	NULL
boiling	NULL
in	NULL
SDS	NULL
sample	NULL
buffer	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
analyzed	NULL
by	NULL
9	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
after	NULL
drying	NULL
the	NULL
gels	NULL
were	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

Some	NULL
in	NULL
vitro	NULL
kinase	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
10	NULL
ug/sample	NULL
poly	NULL
(	NULL
Glu-Tyr	NULL
)	NULL
(	NULL
4:1	NULL
)	NULL
(	NULL
Sigma	NULL
)	NULL
.	NULL

The	NULL
kinase	NULL
reaction	NULL
was	NULL
stopped	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
by	NULL
boiling	NULL
in	NULL
SDS	NULL
sample	NULL
buffer	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
further	NULL
processed	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Western	NULL
Blotting-Western	NULL
blotting	NULL
onto	NULL
nitrocellulose	NULL
membranes	NULL
of	NULL
proteins	NULL
resolved	NULL
by	NULL
SDS-PAGE	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
standard	NULL
procedures	NULL
.	NULL

Protein	NULL
detection	NULL
was	NULL
carried	NULL
out	NULL
by	NULL
incubating	NULL
the	NULL
membranes	NULL
with	NULL
1:1000	NULL
dilutions	NULL
of	NULL
specific	NULL
mAbs	NULL
(	NULL
4610	NULL
,	NULL
PLC-y1	NULL
)	NULL
or	NULL
rabbit	NULL
heteroantisera	NULL
(	NULL
ZAP70	NULL
,	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
p59°	NULL
``	NULL
,	NULL
Pyk2	NULL
,	NULL
pMAPK	NULL
,	NULL
Erkl/	NULL
MAPK	NULL
,	NULL
Raf	NULL
)	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
washed	NULL
with	NULL
TBS/Triton	NULL
X-100	NULL
(	NULL
0.05	NULL
%	NULL
)	NULL
and	NULL
incubated	NULL
with	NULL
1:2000	NULL
dilutions	NULL
of	NULL
HRPO-labeled	NULL
anti-mouse	NULL
IgG2b	NULL
,	NULL
anti-mouse	NULL
IgG	NULL
,	NULL
or	NULL
anti-rabbit	NULL
Abs	NULL
(	NULL
Caltag	NULL
Laboratories	NULL
,	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
,	NULL
respectively	NULL
,	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

After	NULL
washing	NULL
with	NULL
TBS/Triton	NULL
X-100	NULL
,	NULL
the	NULL
proteins	NULL
were	NULL
visualized	NULL
by	NULL
enhanced	NULL
chemiluminescence	NULL
(	NULL
ECL	NULL
Western	NULL
blotting	NULL
detection	NULL
reagents	NULL
,	NULL
Amersham	NULL
International	NULL
,	NULL
Little	NULL
Chalfont	NULL
,	NULL
Bucking-hamshire	NULL
,	NULL
United	NULL
Kingdom	NULL
)	NULL
and	NULL
exposing	NULL
the	NULL
membranes	NULL
to	NULL
films	NULL
for	NULL
various	NULL
time	NULL
intervals	NULL
.	NULL

Unspecific	NULL
binding	NULL
of	NULL
Abs	NULL
was	NULL
inhibited	NULL
by	NULL
preincubating	NULL
the	NULL
membranes	NULL
with	NULL
blocking	NULL
buffer	NULL
(	NULL
TBS	NULL
containing	NULL
either	NULL
5	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
or	NULL
5	NULL
%	NULL
non-fat	NULL
dry	NULL
milk	NULL
and	NULL
10	NULL
mM	NULL
NaN	NULL
,	NULL
)	NULL
for	NULL
at	NULL
least	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Jun	NULL
Kinase	NULL
Assay	NULL
1	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
80	NULL
min	NULL
at	NULL
87°C	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-T11	NULL
,	NULL
and	NULL
anti-T11	NULL
,	NULL
(	NULL
1:100	NULL
)	NULL
,	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
1:100	NULL
)	NULL
,	NULL
or	NULL
25	NULL
ng/ml	NULL
phorbol	NULL
ester	NULL
(	NULL
PMA	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
then	NULL
washed	NULL
with	NULL
ice-cold	NULL
TBS	NULL
and	NULL
lysed	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
100	NULL
ul	NULL
of	NULL
JNK-lysis	NULL
buffer	NULL
(	NULL
25	NULL
mm	NULL
HEPES	NULL
pH	NULL
7.7	NULL
,	NULL
300	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mM	NULL
MgC	NULL
]	NULL
,	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.2	NULL
mm	NULL
EDTA	NULL
,	NULL
2	NULL
pg/ml	NULL
leupeptin	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
1	NULL
mm	NULL
PMSF	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
0.1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
(	NULL
Fisher	NULL
Scientific	NULL
)	NULL
,	NULL
20	NULL
mM	NULL
B-glycerophosphate	NULL
(	NULL
Sigma	NULL
)	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
18,000	NULL
%	NULL
g	NULL
for	NULL
5	NULL
min	NULL
.	NULL

The	NULL
supernatants	NULL
were	NULL
then	NULL
diluted	NULL
1:4	NULL
to	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
20	NULL
mm	NULL
HEPES	NULL
pH	NULL
7.7	NULL
,	NULL
75	NULL
mM	NULL
NaCl	NULL
,	NULL
2.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.05	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
2	NULL
ug/ml	NULL
leupeptin	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
PMSF	NULL
(	NULL
Sigma	NULL
)	NULL
,	NULL
0.1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
(	NULL
Fisher	NULL
Scientific	NULL
)	NULL
,	NULL
20	NULL
mM	NULL
B-glycerophosphate	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
rotated	NULL
for	NULL
4	NULL
h	NULL
at	NULL
4	NULL
°C	NULL
with	NULL
10	NULL
ul	NULL
of	NULL
GammaBind	NULL
Plus-Sepharose	NULL
(	NULL
Pharmacia	NULL
)	NULL
preincubated	NULL
with	NULL
anti-JNK	NULL
Ab	NULL
.	NULL

Bead-bound	NULL
immune	NULL
complexes	NULL
were	NULL
washed	NULL
with	NULL
lysis	NULL
buffer	NULL
and	NULL
kinase	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
20	NULL
mM	NULL
B-glycerophosphate	NULL
,	NULL
0.1	NULL
mM	NULL
Na	NULL
,	NULL
VO	NULL
,	NULL
,	NULL
2	NULL
mM	NULL
DTT	NULL
,	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.4	NULL
)	NULL
and	NULL
subsequently	NULL
resuspended	NULL
in	NULL
50	NULL
ul	NULL
of	NULL
kinase	NULL
buffer	NULL
containing	NULL
20	NULL
uM	NULL
ATP	NULL
and	NULL
2	NULL
pg/sample	NULL
GST-Jun	NULL
fusion	NULL
protein	NULL
(	NULL
kindly	NULL
provided	NULL
by	NULL
M.	NULL
Karin	NULL
)	NULL
and	NULL
were	NULL
incubated	NULL
with	NULL
5	NULL
uCi	NULL
of	NULL
[	NULL
y-*°P	NULL
]	NULL
IATP	NULL
for	NULL
20	NULL
min	NULL
at	NULL
80	NULL
°C	NULL
.	NULL

The	NULL
kinase	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
boiling	NULL
in	NULL
SDS	NULL
(	NULL
Laemmli	NULL
)	NULL
sample	NULL
buffer	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
after	NULL
drying	NULL
the	NULL
gels	NULL
were	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

IL-2	NULL
Production	NULL
Assay	NULL
1	NULL
X	NULL
10°	NULL
cells/well	NULL
were	NULL
stimulated	NULL
in	NULL
Immulon	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
plates	NULL
(	NULL
Dynatech	NULL
Laboratories	NULL
Inc.	NULL
,	NULL
Chantilly	NULL
,	NULL
VA	NULL
)	NULL
with	NULL
either	NULL
PMA	NULL
alone	NULL
(	NULL
25	NULL
ng/ml	NULL
,	NULL
Sigma	NULL
)	NULL
,	NULL
PMA	NULL
plus	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-T11l	NULL
,	NULL
and	NULL
anti-Tll	NULL
,	NULL
(	NULL
1:100	NULL
)	NULL
,	NULL
PMA	NULL
plus	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
RW28CB	NULL
(	NULL
1	NULL
ug/well	NULL
,	NULL
precoated	NULL
overnight	NULL
onto	NULL
the	NULL
plates	NULL
at	NULL
4	NULL
°C	NULL
)	NULL
or	NULL
PMA	NULL
plus	NULL
calcium	NULL
ionophore	NULL
A23187	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
.	NULL

After	NULL
48	NULL
h	NULL
culture	NULL
supernatants	NULL
were	NULL
harvested	NULL
and	NULL
examined	NULL
by	NULL
human	NULL
IL-2	NULL
specific	NULL
enzyme-linked	NULL
immunosorbent	NULL
assays	NULL
(	NULL
Endogen	NULL
Inc.	NULL
,	NULL
Cam	NULL
bridge	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Nuclear	NULL
Extracts	NULL
and	NULL
EMSA	NULL
5	NULL
X	NULL
10	NULL
``	NULL
cells	NULL
,	NULL
unstimulated	NULL
or	NULL
stimulated	NULL
for	NULL
4	NULL
or	NULL
6	NULL
h	NULL
at	NULL
87	NULL
°C	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
stimulatory	NULL
anti-CD2	NULL
(	NULL
anti-T11	NULL
,	NULL
plus	NULL
anti-T1l1	NULL
;	NULL
,	NULL
1:100	NULL
)	NULL
or	NULL
with	NULL
a	NULL
1:100	NULL
dilution	NULL
of	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
,	NULL
were	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
15	NULL
min	NULL
with	NULL
400	NULL
pl	NULL
of	NULL
ice-cold	NULL
Buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
pH	NULL
7.9	NULL
,	NULL
10	NULL
mm	NULL
KCl	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
0.2	NULL
mm	NULL
PMSF	NULL
)	NULL
and	NULL
spun	NULL
at	NULL
13,000	NULL
rpm	NULL
for	NULL
10	NULL
s.	NULL
The	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
ice-cold	NULL
buffer	NULL
C	NULL
(	NULL
10	NULL
mm	NULL
HEPES	NULL
pH	NULL
7.9	NULL
,	NULL
420	NULL
mM	NULL
NaCl	NULL
,	NULL
1.5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
25	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.2	NULL
mM	NULL
PMSF	NULL
)	NULL
and	NULL
left	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
.	NULL

After	NULL
spinning	NULL
for	NULL
5	NULL
min	NULL
at	NULL
full	NULL
speed	NULL
,	NULL
the	NULL
supernatants	NULL
were	NULL
removed	NULL
,	NULL
aliquoted	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
in	NULL
the	NULL
supernatants	NULL
was	NULL
determined	NULL
by	NULL
BCA	NULL
Assay	NULL
(	NULL
Pierce	NULL
)	NULL
and	NULL
10	NULL
ug/sample	NULL
were	NULL
used	NULL
in	NULL
the	NULL
EMSA	NULL
.	NULL

The	NULL
double-stranded	NULL
oligonucleotides	NULL
(	NULL
APL	NULL
consensus	NULL
,	NULL
NF-kB	NULL
consensus	NULL
,	NULL
NF-AT	NULL
consensus	NULL
,	NULL
and	NULL
Oct	NULL
1	NULL
consensus	NULL
)	NULL
and	NULL
the	NULL
Abs	NULL
for	NULL
the	NULL
supershifts	NULL
(	NULL
anti-c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
JunD	NULL
,	NULL
c-Fos	NULL
,	NULL
FRAL	NULL
,	NULL
FRA2	NULL
,	NULL
Fos-B	NULL
,	NULL
NF-kB	NULL
p50	NULL
and	NULL
p65	NULL
)	NULL
used	NULL
in	NULL
these	NULL
EMSA	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
.	NULL

10	NULL
ug	NULL
of	NULL
NE	NULL
were	NULL
incubated	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
mm	NULL
HEPES	NULL
pH	NULL
7.5	NULL
,	NULL
30	NULL
mM	NULL
KCI	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
12	NULL
%	NULL
(	NULL
v/v	NULL
)	NULL
glycerol	NULL
,	NULL
0.5	NULL
mm	NULL
DTT	NULL
,	NULL
0.2	NULL
mM	NULL
PMSF	NULL
)	NULL
for	NULL
30	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
2	NULL
ug	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
(	NULL
Boehringer	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
aCD2	NULL
aCD3e	NULL
J77	NULL
i	NULL
©	NULL
3	NULL
%	NULL
JCaM1.6s	NULL
{	NULL
__	NULL
gp	NULL
£00	NULL
UE	NULL
j	NULL
0	NULL
1	NULL
2	NULL
3	NULL
0	NULL
1	NULL
2	NULL
3	NULL
Log	NULL
Fluorescence	NULL
J77	NULL
__	NULL
JCaM1.6s	NULL
Fo	NULL
--	NULL
aCD2	NULL
aCD3	NULL
Ab	NULL
®	NULL
~	NULL
o	NULL
0	NULL
~-	NULL
3	NULL
8	NULL
T	NULL
Ick-£	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

The	NULL
phenotype	NULL
and	NULL
p56	NULL
``	NULL
*	NULL
in	NULL
vitro	NULL
kinase	NULL
activity	NULL
of	NULL
J77	NULL
and	NULL
JCaM1.6s	NULL
.	NULL

A	NULL
,	NULL
J77	NULL
(	NULL
parental	NULL
Jurkat	NULL
cells	NULL
)	NULL
and	NULL
JCaM1.6s	NULL
cells	NULL
were	NULL
stained	NULL
with	NULL
anti-T1l1l	NULL
,	NULL
(	NULL
anti-CD2	NULL
)	NULL
or	NULL
RW28C8	NULL
(	NULL
anti-CD8e	NULL
)	NULL
mAbs	NULL
and	NULL
analyzed	NULL
on	NULL
a	NULL
FACScan	NULL
.	NULL

The	NULL
x	NULL
axis	NULL
indicates	NULL
the	NULL
log	NULL
fluorescence	NULL
intensity	NULL
.	NULL

Equal	NULL
expression	NULL
of	NULL
CD2	NULL
or	NULL
CD3	NULL
is	NULL
shown	NULL
for	NULL
both	NULL
cell	NULL
lines	NULL
.	NULL

B	NULL
,	NULL
J77	NULL
or	NULL
JCaM1.6s	NULL
cells	NULL
were	NULL
left	NULL
unstimulated	NULL
or	NULL
were	NULL
stimulated	NULL
via	NULL
eCD2	NULL
(	NULL
anti-Tl1l	NULL
,	NULL
plus	NULL
anti-T1l	NULL
,	NULL
mAbs	NULL
)	NULL
or	NULL
aCD8e	NULL
(	NULL
2AD2A2	NULL
mAb	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
a	NULL
p56**-specific	NULL
antiserum	NULL
,	NULL
subjected	NULL
to	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
and	NULL
analyzed	NULL
on	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
migration	NULL
position	NULL
of	NULL
p56'*	NULL
.	NULL

Mannheim	NULL
)	NULL
and	NULL
either	NULL
2	NULL
ul	NULL
of	NULL
the	NULL
respective	NULL
Ab	NULL
or	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
oligonucleotide	NULL
as	NULL
competitor	NULL
.	NULL

Subsequently	NULL
,	NULL
0.5	NULL
ng	NULL
of	NULL
*°P-labeled	NULL
oligo	NULL
were	NULL
added	NULL
and	NULL
incubated	NULL
with	NULL
the	NULL
NE	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
an	NULL
additional	NULL
20	NULL
min	NULL
.	NULL

The	NULL
proteins	NULL
were	NULL
separated	NULL
on	NULL
5.2	NULL
(	NULL
EMSA	NULL
)	NULL
or	NULL
4	NULL
%	NULL
(	NULL
supershift	NULL
)	NULL
gels	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
subjected	NULL
to	NULL
autoradiography	NULL
.	NULL

RESULTS	NULL
The	NULL
CD2P	NULL
``	NULL
CD3P	NULL
``	NULL
*	NULL
JCaM1.6s	NULL
Cells	NULL
do	NULL
Not	NULL
Express	NULL
p56*_-JCaM1IL.6	NULL
is	NULL
a	NULL
Jurkat	NULL
cell	NULL
line	NULL
variant	NULL
,	NULL
which	NULL
lacks	NULL
functional	NULL
p56	NULL
``	NULL
and	NULL
is	NULL
unresponsive	NULL
to	NULL
TCR	NULL
stimulation	NULL
such	NULL
that	NULL
it	NULL
fails	NULL
to	NULL
generate	NULL
IL-2	NULL
upon	NULL
anti-CD3	NULL
cross-linking	NULL
(	NULL
42	NULL
)	NULL
.	NULL

To	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
different	NULL
TCR	NULL
and/or	NULL
CD2	NULL
surface	NULL
expression	NULL
levels	NULL
between	NULL
Jurkat	NULL
and	NULL
JCaM1.6	NULL
might	NULL
account	NULL
for	NULL
a	NULL
component	NULL
of	NULL
the	NULL
signaling	NULL
defect	NULL
,	NULL
JCaM1L.6	NULL
cells	NULL
were	NULL
sorted	NULL
on	NULL
a	NULL
FACSVantage	NULL
for	NULL
high	NULL
co-expression	NULL
of	NULL
both	NULL
CD2	NULL
and	NULL
CD3	NULL
,	NULL
equivalent	NULL
to	NULL
the	NULL
surface	NULL
expression	NULL
number	NULL
of	NULL
these	NULL
receptors	NULL
found	NULL
on	NULL
the	NULL
Jurkat	NULL
line	NULL
J77	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
)	NULL
.	NULL

The	NULL
sorted	NULL
JCaM1IL.6	NULL
(	NULL
referred	NULL
to	NULL
as	NULL
JCaM1.6s	NULL
)	NULL
as	NULL
well	NULL
as	NULL
JCaM1.6s	NULL
cells	NULL
,	NULL
further	NULL
sorted	NULL
for	NULL
maximal	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
upon	NULL
CD2	NULL
cross-linking	NULL
(	NULL
termed	NULL
JCaM1.6s.83	NULL
)	NULL
,	NULL
were	NULL
analyzed	NULL
by	NULL
in	NULL
vifro	NULL
kinase	NULL
assay	NULL
for	NULL
p56	NULL
``	NULL
**	NULL
autophosphorylation	NULL
and	NULL
poly	NULL
(	NULL
Glu-Tyr	NULL
)	NULL
substrate	NULL
phosphorylation	NULL
activity	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
and	NULL
in	NULL
contrast	NULL
to	NULL
J77	NULL
,	NULL
JCaM1.6s	NULL
does	NULL
not	NULL
express	NULL
detectable	NULL
amounts	NULL
of	NULL
functional	NULL
p56	NULL
``	NULL
*	NULL
,	NULL
as	NULL
judged	NULL
by	NULL
in	NULL
vitro	NULL
autophosphorylation	NULL
of	NULL
unstimulated	NULL
,	NULL
anti-CD2-	NULL
,	NULL
or	NULL
anti-CD3e-stimulated	NULL
JCaM1.6s	NULL
cells	NULL
.	NULL

Similarly	NULL
,	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
,	NULL
anti-p56	NULL
``	NULL
*	NULL
antibody	NULL
immunoprecipitates	NULL
from	NULL
JCaM1.6s.83	NULL
cells	NULL
do	NULL
not	NULL
reveal	NULL
autophosphorylation	NULL
activity	NULL
or	NULL
any	NULL
enzymatic	NULL
activity	NULL
using	NULL
the	NULL
poly	NULL
(	NULL
Glu-Tyr	NULL
)	NULL
substrate	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CD2	NULL
Stimulation	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
p56	NULL
``	NULL
Leads	NULL
to	NULL
a	NULL
Prolonged	NULL
and	NULL
High	NULL
Amplitude	NULL
Rise	NULL
in	NULL
Intracellular	NULL
Free	NULL
Ca	NULL
``	NULL
*-Although	NULL
TCR	NULL
cross-linking	NULL
by	NULL
anti-CD3e	NULL
mAb	NULL
or	NULL
anticlono-typic	NULL
mAb	NULL
does	NULL
not	NULL
activate	NULL
JCaM1L.6	NULL
cells	NULL
(	NULL
42	NULL
)	NULL
,	NULL
the	NULL
status	NULL
of	NULL
the	NULL
CD2	NULL
pathway	NULL
in	NULL
these	NULL
cells	NULL
was	NULL
not	NULL
defined	NULL
.	NULL

To	NULL
first	NULL
address	NULL
the	NULL
integrity	NULL
of	NULL
CD2	NULL
mediated	NULL
signaling	NULL
,	NULL
we	NULL
analyzed	NULL
24251	NULL
J77	NULL
Avidin	NULL
.	NULL

lonophore	NULL
aCD8e	NULL
biot	NULL
.	NULL

B	NULL
WB	NULL
:	NULL
apTyr	NULL
aPLC-y1	NULL
J77	NULL
JCaM1.6s	NULL
J77	NULL
JCaM1.6s	NULL
U	NULL
u	NULL
1	NULL
U	NULL
if	NULL
ou	NULL
co	NULL
ou	NULL
ou	NULL
ou	NULL
co	NULL
£s	NULL
§§	NULL
-T	NULL
?	NULL

-	NULL
%	NULL
%	NULL
PLO-Yl—b-	NULL
ame	NULL
cap	NULL
r	NULL
|	NULL
Wo	NULL
we	NULL
wage	NULL
foams	NULL
com	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Analysis	NULL
of	NULL
[	NULL
Ca®	NULL
``	NULL
*	NULL
]	NULL
,	NULL
;	NULL
in	NULL
J77	NULL
and	NULL
JCaM1.6s.83	NULL
.	NULL

A	NULL
,	NULL
Ca**	NULL
mobilization	NULL
in	NULL
J77	NULL
and	NULL
JCaM1.6s.33	NULL
.	NULL

Cells	NULL
were	NULL
loaded	NULL
with	NULL
Indo-1	NULL
.	NULL

Calcium	NULL
flux	NULL
was	NULL
then	NULL
analyzed	NULL
on	NULL
an	NULL
EPICS	NULL
V	NULL
flow	NULL
cytometer	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-T11	NULL
,	NULL
plus	NULL
anti-T11	NULL
,	NULL
(	NULL
CD2	NULL
)	NULL
or	NULL
biotinylated	NULL
anti-CD8e	NULL
mAb	NULL
RW28C8	NULL
(	NULL
aCDSebiot	NULL
)	NULL
,	NULL
avidin	NULL
,	NULL
and	NULL
Ca	NULL
``	NULL
*	NULL
ionophore	NULL
were	NULL
added	NULL
sequentially	NULL
.	NULL

B	NULL
,	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
in	NULL
J77	NULL
and	NULL
JCaM1.6s.88	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti-CD2	NULL
mAbs	NULL
or	NULL
the	NULL
anti-CD3e	NULL
mAb	NULL
2AD2A2	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
anti-PLC-y1	NULL
Ab	NULL
.	NULL

Immunoprecipitates	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
mAb	NULL
4G10	NULL
(	NULL
eft	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
stripped	NULL
blots	NULL
were	NULL
subsequently	NULL
immunoblotted	NULL
with	NULL
PLC-y1	NULL
Ab	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
migration	NULL
position	NULL
of	NULL
PLC-y1	NULL
is	NULL
indicated	NULL
by	NULL
the	NULL
arrows	NULL
(	NULL
at	NULL
~135	NULL
kDa	NULL
)	NULL
.	NULL

Ca	NULL
``	NULL
*	NULL
mobilization	NULL
in	NULL
both	NULL
JCaM1.6s	NULL
,	NULL
the	NULL
Ca**	NULL
sorted	NULL
JCaM1.6	NULL
s.83	NULL
and	NULL
J77	NULL
following	NULL
anti-CD2	NULL
or	NULL
anti-CD3e	NULL
stimulation	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
J77	NULL
,	NULL
in	NULL
which	NULL
both	NULL
anti-CD2	NULL
and	NULL
anti-CD3e	NULL
mAbs	NULL
induced	NULL
a	NULL
long	NULL
lasting	NULL
and	NULL
high	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
,	NULL
only	NULL
anti-CD2	NULL
stimulation	NULL
via	NULL
the	NULL
combination	NULL
of	NULL
anti-Tl1l	NULL
;	NULL
plus	NULL
anti-Tl1l	NULL
;	NULL
,	NULL
mAbs	NULL
resulted	NULL
in	NULL
a	NULL
substantial	NULL
Ca**	NULL
influx	NULL
in	NULL
JCaM1.6s	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

After	NULL
sorting	NULL
,	NULL
the	NULL
Ca**	NULL
response	NULL
of	NULL
JCaM1.6s.83	NULL
to	NULL
anti-CD2	NULL
stimulation	NULL
was	NULL
equal	NULL
or	NULL
even	NULL
higher	NULL
than	NULL
in	NULL
J77	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Addition	NULL
of	NULL
biotinylated	NULL
anti-CD3e	NULL
mAb	NULL
alone	NULL
was	NULL
not	NULL
sufficient	NULL
for	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
in	NULL
JCaM1L.6s	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
or	NULL
in	NULL
JCaM1.6s.83	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

Rather	NULL
extensive	NULL
cross-linking	NULL
of	NULL
the	NULL
biotinylated	NULL
anti-CD3e	NULL
mAb	NULL
by	NULL
avidin	NULL
was	NULL
required	NULL
to	NULL
lead	NULL
to	NULL
a	NULL
detectable	NULL
Ca**	NULL
transient	NULL
.	NULL

This	NULL
appears	NULL
as	NULL
a	NULL
low	NULL
magnitude	NULL
rise	NULL
in	NULL
Ca**	NULL
of	NULL
short	NULL
duration	NULL
and	NULL
most	NULL
probably	NULL
is	NULL
due	NULL
to	NULL
the	NULL
initial	NULL
release	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
stores	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
(	NULL
41	NULL
,	NULL
44	NULL
,	NULL
45	NULL
)	NULL
.	NULL

PLC-y1	NULL
Is	NULL
Tyrosine	NULL
Phosphorylated	NULL
and	NULL
Activated	NULL
by	NULL
CD2	NULL
Stimulation	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
p56	NULL
'	NULL
``	NULL
``	NULL
*-Given	NULL
that	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
PLC-y1	NULL
leads	NULL
to	NULL
increased	NULL
phosphatidylinositol	NULL
turnover	NULL
and	NULL
the	NULL
release	NULL
of	NULL
Ca**	NULL
from	NULL
intracellular	NULL
Ca*	NULL
``	NULL
*	NULL
stores	NULL
(	NULL
45	NULL
,	NULL
46	NULL
)	NULL
,	NULL
the	NULL
phosphorylation	NULL
status	NULL
of	NULL
PLC-y1	NULL
was	NULL
determined	NULL
prior	NULL
to	NULL
and	NULL
following	NULL
stimulation	NULL
in	NULL
the	NULL
J77	NULL
and	NULL
JCaM1.6s	NULL
cells	NULL
.	NULL

In	NULL
J77	NULL
,	NULL
the	NULL
stimulation	NULL
via	NULL
both	NULL
CD2	NULL
and	NULL
CD3e	NULL
results	NULL
in	NULL
a	NULL
strong	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-yl	NULL
as	NULL
shown	NULL
by	NULL
anti-Tyr	NULL
(	NULL
P	NULL
)	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
anti-PLC-yl	NULL
immunoprecipitations	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
only	NULL
activation	NULL
via	NULL
CD2	NULL
leads	NULL
to	NULL
a	NULL
clear	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
in	NULL
JCaM1.6s	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
,	NULL
whereas	NULL
anti-CD3€	NULL
stimulation	NULL
had	NULL
a	NULL
minor	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

These	NULL
differences	NULL
were	NULL
not	NULL
a	NULL
consequence	NULL
of	NULL
gel	NULL
loading	NULL
of	NULL
the	NULL
anti-PLC-y1	NULL
immunoprecipitates	NULL
as	NULL
revealed	NULL
by	NULL
sequential	NULL
Western	NULL
blotting	NULL
with	NULL
anti-PLC-y1	NULL
antibody	NULL
.	NULL

CD2	NULL
but	NULL
Not	NULL
CD3	NULL
Stimulation	NULL
Results	NULL
in	NULL
Interleukin	NULL
2	NULL
Produc-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
24252	NULL
TaBLE	NULL
I	NULL
CD2	NULL
triggering	NULL
induces	NULL
IL-2	NULL
production	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p56	NULL
``	NULL
Cell	NULL
culture	NULL
supernatants	NULL
were	NULL
analyzed	NULL
for	NULL
IL-2	NULL
content	NULL
after	NULL
48	NULL
h	NULL
stimulation	NULL
with	NULL
A23187	NULL
,	NULL
a-CD3e	NULL
mAb	NULL
RW28C8	NULL
,	NULL
or	NULL
«	NULL
-CD2	NULL
mAbs	NULL
anti-T11	NULL
,	NULL
plus	NULL
anti-T11l	NULL
;	NULL
;	NULL
or	NULL
after	NULL
no	NULL
stimulation	NULL
(	NULL
none	NULL
)	NULL
.	NULL

PMA	NULL
was	NULL
added	NULL
to	NULL
all	NULL
wells	NULL
at	NULL
25	NULL
ng/ml	NULL
.	NULL

S.D	NULL
.	NULL

of	NULL
triplicate	NULL
samples	NULL
<	NULL
5	NULL
%	NULL
for	NULL
all	NULL
entries	NULL
.	NULL

IL-2	NULL
(	NULL
ng/m1	NULL
)	NULL
Stimulus	NULL
None	NULL
A23187	NULL
a-CD8e	NULL
a-CD2	NULL
J77	NULL
0.05	NULL
17.95	NULL
6.17	NULL
23.56	NULL
JCaM1.6s	NULL
0.01	NULL
6.09	NULL
0.08	NULL
2.60	NULL
JCaM1.6s.81	NULL
0.01	NULL
5.77	NULL
0.09	NULL
2.77	NULL
JCaM1.6s.92	NULL
0.05	NULL
14.39	NULL
0.17	NULL
7.36	NULL
JCaM1.6s.93	NULL
0.083	NULL
43.176	NULL
0.16	NULL
21.13	NULL
tion	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
p56	NULL
``	NULL
*-To	NULL
next	NULL
determine	NULL
whether	NULL
the	NULL
CD2	NULL
pathway	NULL
in	NULL
JCaM1.6s	NULL
could	NULL
elicit	NULL
IL-2	NULL
production	NULL
,	NULL
we	NULL
determined	NULL
the	NULL
levels	NULL
of	NULL
IL-2	NULL
secretion	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
anti-CD2	NULL
stimulated	NULL
JCaM1.6s	NULL
cells	NULL
in	NULL
a	NULL
human	NULL
IL-2	NULL
specific	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
and	NULL
by	NULL
intracellular	NULL
staining	NULL
of	NULL
IL-2	NULL
in	NULL
these	NULL
stimulated	NULL
JCaM1.6s	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Parallel	NULL
analysis	NULL
was	NULL
performed	NULL
in	NULL
the	NULL
same	NULL
cells	NULL
following	NULL
anti-CD3e	NULL
mAb	NULL
stimulation	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
I	NULL
,	NULL
stimulation	NULL
via	NULL
CD2	NULL
in	NULL
JCaM1.6s	NULL
cells	NULL
results	NULL
in	NULL
substantial	NULL
IL-2	NULL
production	NULL
,	NULL
in	NULL
fact	NULL
to	NULL
a	NULL
level	NULL
equivalent	NULL
to	NULL
50	NULL
%	NULL
of	NULL
the	NULL
maximal	NULL
induction	NULL
measured	NULL
upon	NULL
bypassing	NULL
receptor	NULL
triggering	NULL
with	NULL
the	NULL
combination	NULL
of	NULL
calcium	NULL
ionophore	NULL
plus	NULL
PMA	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
and	NULL
as	NULL
expected	NULL
,	NULL
no	NULL
IL-2	NULL
production	NULL
is	NULL
induced	NULL
by	NULL
TCR	NULL
cross-linking	NULL
by	NULL
anti-CD3e	NULL
.	NULL

Data	NULL
from	NULL
different	NULL
subclones	NULL
of	NULL
JCaM1.6s	NULL
obtained	NULL
by	NULL
sequential	NULL
sorting	NULL
for	NULL
Ca*	NULL
``	NULL
mobilization	NULL
following	NULL
CD2	NULL
stimulation	NULL
are	NULL
shown	NULL
(	NULL
JCaM1L.6s.81	NULL
,	NULL
JCaM1.6s.82	NULL
,	NULL
and	NULL
JCaMIL.6s.83	NULL
)	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
IL-2	NULL
produced	NULL
increases	NULL
with	NULL
enhanced	NULL
Ca**	NULL
responsiveness	NULL
to	NULL
CD2	NULL
stimulation	NULL
.	NULL

Neither	NULL
p59	NULL
``	NULL
nor	NULL
ZAP7O	NULL
Are	NULL
Detectably	NULL
Tyrosine	NULL
Phosphorylated	NULL
following	NULL
CD2	NULL
Stimulation	NULL
in	NULL
JCaM1.6s-Tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
kinases	NULL
such	NULL
as	NULL
the	NULL
Src	NULL
kinases	NULL
p56	NULL
``	NULL
**	NULL
or	NULL
p59	NULL
``	NULL
or	NULL
the	NULL
related	NULL
tyrosine	NULL
kinase	NULL
ZAP70	NULL
are	NULL
major	NULL
events	NULL
in	NULL
TCR	NULL
signaling	NULL
and	NULL
are	NULL
also	NULL
thought	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
signal	NULL
transduction	NULL
via	NULL
CD2	NULL
(	NULL
47	NULL
)	NULL
.	NULL

The	NULL
Jurkat	NULL
variant	NULL
JCaM1L.6s	NULL
gives	NULL
us	NULL
the	NULL
opportunity	NULL
to	NULL
investigate	NULL
these	NULL
events	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
we	NULL
performed	NULL
a	NULL
series	NULL
of	NULL
Western	NULL
blots	NULL
with	NULL
J77	NULL
and	NULL
JCaM1.6s	NULL
cells	NULL
following	NULL
anti-CD2	NULL
or	NULL
anti-CD3e	NULL
stimulation	NULL
.	NULL

In	NULL
J77	NULL
,	NULL
activation	NULL
via	NULL
both	NULL
CD2	NULL
and	NULL
CD3	NULL
results	NULL
in	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
p56	NULL
``	NULL
*	NULL
and	NULL
the	NULL
appearance	NULL
of	NULL
a	NULL
second	NULL
p60	NULL
``	NULL
*	NULL
band	NULL
due	NULL
to	NULL
the	NULL
serine/	NULL
threonine	NULL
phosphorylation	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
(	NULL
48	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
both	NULL
ick	NULL
bands	NULL
are	NULL
absent	NULL
in	NULL
the	NULL
phosphotyrosine	NULL
blot	NULL
of	NULL
p56**	NULL
immunoprecipitates	NULL
from	NULL
JCaM1.6s	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
p58	NULL
band	NULL
appearing	NULL
in	NULL
the	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
blot	NULL
of	NULL
both	NULL
J77	NULL
and	NULL
JCaM1.6s	NULL
is	NULL
nonspecific	NULL
,	NULL
being	NULL
unrelated	NULL
to	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

Reanalysis	NULL
of	NULL
the	NULL
stripped	NULL
blot	NULL
with	NULL
anti-lck	NULL
antiserum	NULL
shows	NULL
that	NULL
these	NULL
p56-	NULL
and	NULL
p6O-phosphorylated	NULL
proteins	NULL
in	NULL
J77	NULL
indeed	NULL
represent	NULL
p56	NULL
``	NULL
(	NULL
Fig	NULL
.	NULL

3A	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
J77	NULL
,	NULL
stimulation	NULL
via	NULL
the	NULL
CD3	NULL
pathway	NULL
leads	NULL
to	NULL
a	NULL
strong	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
ZAP70	NULL
,	NULL
whereas	NULL
activation	NULL
via	NULL
CD2	NULL
induces	NULL
weaker	NULL
but	NULL
definite	NULL
ZAPT7O	NULL
phosphorylation	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
this	NULL
observation	NULL
,	NULL
in	NULL
JCaM1IL.6s	NULL
neither	NULL
CD2	NULL
nor	NULL
CD3	NULL
stimulation	NULL
induce	NULL
the	NULL
phosphorylation	NULL
of	NULL
ZAPT70	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
similar	NULL
amounts	NULL
of	NULL
ZAP70	NULL
were	NULL
immunoprecipitated	NULL
in	NULL
each	NULL
lane	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
results	NULL
of	NULL
reprobing	NULL
the	NULL
stripped	NULL
Tyr	NULL
(	NULL
P	NULL
)	NULL
blot	NULL
with	NULL
an	NULL
anti-ZAP7O0	NULL
rabbit	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

In	NULL
both	NULL
J77	NULL
and	NULL
JCaM1.6s	NULL
,	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
p59	NULL
``	NULL
increases	NULL
minimally	NULL
if	NULL
at	NULL
all	NULL
after	NULL
either	NULL
CD2	NULL
or	NULL
CD3	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
upper	NULL
panel	NULL
)	NULL
.	NULL

The	NULL
corresponding	NULL
p59	NULL
``	NULL
``	NULL
blot	NULL
probed	NULL
with	NULL
anti-p59	NULL
``	NULL
``	NULL
antibody	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3C	NULL
,	NULL
lower	NULL
panel	NULL
.	NULL

Note	NULL
that	NULL
the	NULL
band	NULL
below	NULL
p59	NULL
``	NULL
is	NULL
related	NULL
to	NULL
immuno-globulin	NULL
heavy	NULL
chain	NULL
.	NULL

p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
J77	NULL
JCaM1.6s	NULL
OU	NULL
co	NULL
~	NULL
6	NULL
8	NULL
-	NULL
§	NULL
8	NULL
IP	NULL
-	NULL
3	NULL
5	NULL
_	NULL
5	NULL
30	NULL
WB	NULL
A	NULL
alck	NULL
lot	NULL
t	NULL
)	NULL
M	NULL
MI	NULL
S	NULL
2	NULL
S	NULL
aptyr	NULL
Ick	NULL
£	NULL
_	NULL
.	NULL

**	NULL
%	NULL
alck	NULL
B	NULL
yap	NULL
EN	NULL
’	NULL
W—F	NULL
'	NULL
wo	NULL
«	NULL
tis	NULL
upTyr	NULL
a	NULL
ZAPTQ	NULL
-	NULL
»	NULL
was	NULL
«	NULL
on	NULL
«	NULL
-	NULL
.	NULL

mae	NULL
mak	NULL
ame	NULL
~	NULL
cant	NULL
'-	NULL
apTyr	NULL
n+	NULL
usin	NULL
meee	NULL
ofyn	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Analysis	NULL
of	NULL
protein-tyrosine	NULL
kinase	NULL
activation	NULL
in	NULL
J77	NULL
and	NULL
JCaM1.6s.83	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-T11	NULL
,	NULL
plus	NULL
anti-T1l	NULL
,	NULL
(	NULL
«	NULL
CD2	NULL
)	NULL
or	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
aCD3	NULL
)	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
antisera	NULL
specific	NULL
for	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
ZAP70	NULL
,	NULL
or	NULL
p59*	NULL
``	NULL
,	NULL
respectively	NULL
.	NULL

Immunoprecipitates	NULL
in	NULL
panels	NULL
A-C	NULL
using	NULL
the	NULL
designated	NULL
Abs	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
anti-phosphotyrosine	NULL
mAb	NULL
4G10	NULL
(	NULL
upper	NULL
row	NULL
)	NULL
.	NULL

The	NULL
blots	NULL
were	NULL
stripped	NULL
and	NULL
subsequently	NULL
immunoblotted	NULL
with	NULL
the	NULL
respective	NULL
Abs	NULL
(	NULL
low-er	NULL
row	NULL
)	NULL
.	NULL

The	NULL
migration	NULL
positions	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
ZAP70	NULL
,	NULL
or	NULL
p59	NULL
``	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

im-	NULL
»	NULL
Eg	NULL
!	NULL

C	NULL
afyn	NULL
The	NULL
Ras-MAPK	NULL
Pathway	NULL
Is	NULL
Not	NULL
Functional	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
p56	NULL
``	NULL
*-TCR	NULL
stimulation	NULL
of	NULL
T	NULL
cells	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
Ras	NULL
resulting	NULL
in	NULL
the	NULL
serine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Raf	NULL
,	NULL
then	NULL
subsequently	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
signaling	NULL
cascade	NULL
and	NULL
finally	NULL
to	NULL
the	NULL
initiation	NULL
of	NULL
IL-2	NULL
transcription	NULL
(	NULL
49	NULL
)	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
activation	NULL
of	NULL
Raf	NULL
and	NULL
MAPK	NULL
by	NULL
Western	NULL
blotting	NULL
of	NULL
the	NULL
total	NULL
lysate	NULL
of	NULL
either	NULL
unstimulated	NULL
or	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
stimulated	NULL
J77	NULL
or	NULL
JCaM1L.6s.53	NULL
cells	NULL
with	NULL
rabbit	NULL
antisera	NULL
specific	NULL
for	NULL
Raf	NULL
,	NULL
pMAPK	NULL
,	NULL
or	NULL
MAPK	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A-C	NULL
)	NULL
.	NULL

In	NULL
J77	NULL
,	NULL
both	NULL
CD2	NULL
and	NULL
CD3	NULL
stimulation	NULL
induced	NULL
the	NULL
phosphorylation	NULL
and	NULL
molecular	NULL
weight	NULL
shift	NULL
of	NULL
Raf	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
and	NULL
the	NULL
subsequent	NULL
phosphorylation	NULL
of	NULL
MAPK	NULL
as	NULL
shown	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
antisera	NULL
specific	NULL
for	NULL
the	NULL
phospho-MAPK	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
in	NULL
JCaM1.6s.83	NULL
stimulation	NULL
via	NULL
CD2	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
either	NULL
kinase	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
anti-CD3	NULL
triggering	NULL
in	NULL
JCaM1.6s.83	NULL
led	NULL
to	NULL
the	NULL
phosphorylation	NULL
and	NULL
molecular	NULL
weight	NULL
shift	NULL
of	NULL
Raf	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
but	NULL
not	NULL
to	NULL
the	NULL
functional	NULL
activation	NULL
of	NULL
Raf	NULL
as	NULL
judged	NULL
by	NULL
the	NULL
very	NULL
low	NULL
or	NULL
absent	NULL
phosphorylation	NULL
of	NULL
MAPK	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4C	NULL
by	NULL
sequential	NULL
immunoblotting	NULL
with	NULL
a	NULL
MAPK	NULL
specific	NULL
antiserum	NULL
,	NULL
the	NULL
described	NULL
differences	NULL
were	NULL
not	NULL
due	NULL
to	NULL
different	NULL
amounts	NULL
of	NULL
MAPK	NULL
in	NULL
the	NULL
total	NULL
lysates	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
J77	NULL
,	NULL
but	NULL
not	NULL
in	NULL
JCaM1L.6s.983	NULL
,	NULL
stimulation	NULL
via	NULL
either	NULL
CD2	NULL
or	NULL
CD3	NULL
enhanced	NULL
the	NULL
kinase	NULL
activity	NULL
of	NULL
MAPK	NULL
toward	NULL
myelin	NULL
basic	NULL
protein	NULL
in	NULL
an	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
CD2	NULL
stimulated	NULL
IL-2	NULL
production	NULL
in	NULL
JCaM1.6s.83	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
coculture	NULL
with	NULL
the	NULL
MEK1-inhibitor	NULL
PD98059	NULL
,	NULL
which	NULL
interferes	NULL
with	NULL
the	NULL
MAPK	NULL
pathway	NULL
upstream	NULL
of	NULL
MAPK	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CD2	NULL
but	NULL
Not	NULL
CD3	NULL
Stimulation	NULL
Activates	NULL
Jun	NULL
Kinase	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
p56**-Initiation	NULL
of	NULL
IL-2	NULL
transcription	NULL
requires	NULL
the	NULL
binding	NULL
of	NULL
certain	NULL
DNA-binding	NULL
proteins	NULL
to	NULL
specific	NULL
regions	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
50	NULL
)	NULL
.	NULL

One	NULL
of	NULL
these	NULL
DNA-binding	NULL
elements	NULL
is	NULL
the	NULL
AP-1	NULL
complex	NULL
,	NULL
which	NULL
consists	NULL
of	NULL
homo-	NULL
or	NULL
heterodimers	NULL
of	NULL
members	NULL
of	NULL
the	NULL
Jun	NULL
and	NULL
Fos	NULL
protein	NULL
family	NULL
(	NULL
51	NULL
)	NULL
.	NULL

In	NULL
order	NULL
to	NULL
bind	NULL
to	NULL
and	NULL
activate	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
these	NULL
dimers	NULL
must	NULL
assemble	NULL
and	NULL
the	NULL
participating	NULL
proteins	NULL
become	NULL
phosphorylated	NULL
(	NULL
51	NULL
)	NULL
.	NULL

Jun	NULL
kinase	NULL
(	NULL
JNK	NULL
)	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
serine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
Jun	NULL
family	NULL
members	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Following	NULL
CD2	NULL
stimulation	NULL
in	NULL
JCaM1.6s.83	NULL
cells	NULL
,	NULL
activation	NULL
of	NULL
JNK	NULL
is	NULL
readily	NULL
detected	NULL
as	NULL
shown	NULL
by	NULL
in	NULL
vitro	NULL
kinase	NULL
activity	NULL
using	NULL
a	NULL
GST-Jun	NULL
fusion	NULL
protein	NULL
substrate	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

CD3	NULL
stimulation	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
J77	NULL
___	NULL
JCaM1.6s.983	NULL
``	NULL
__	NULL
_I	NULL
a	NULL
``	NULL
a	NULL
a	NULL
``	NULL
[	NULL
9	NULL
co	NULL
Cd	NULL
Co	NULL
+	NULL
§	NULL
§	NULL
-	NULL
§	NULL
§	NULL
T	NULL
§	NULL
§	NULL
T	NULL
§	NULL
§	NULL
WB	NULL
-	NULL
>	NULL
youth	NULL
A	NULL
raf	NULL
pa	NULL
«	NULL
was	NULL
otk	NULL
v	NULL
araf	NULL
BMAPKi	NULL
TC	NULL
a	NULL
pMAPK	NULL
C	NULL
mark	NULL
-	NULL
cvark	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
MAPK	NULL
pathway	NULL
in	NULL
J77	NULL
and	NULL
JCaM1.6s.83	NULL
.	NULL

Cells	NULL
were	NULL
either	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-Tl1l	NULL
,	NULL
plus	NULL
anti-Tl1	NULL
,	NULL
(	NULL
aCD2	NULL
)	NULL
or	NULL
the	NULL
anti-CDS3e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
«	NULL
CD3	NULL
)	NULL
and	NULL
total	NULL
lysates	NULL
were	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
WB	NULL
)	NULL
with	NULL
antisera	NULL
specific	NULL
for	NULL
Raf	NULL
(	NULL
A	NULL
)	NULL
or	NULL
phosphorylated	NULL
MAPK	NULL
(	NULL
pMAPK	NULL
)	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
pMAPK	NULL
blot	NULL
was	NULL
stripped	NULL
and	NULL
subsequently	NULL
immunoblotted	NULL
with	NULL
an	NULL
antiserum	NULL
specific	NULL
for	NULL
MAPK	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
migration	NULL
position	NULL
of	NULL
Raf	NULL
(	NULL
at	NULL
~74	NULL
kDa	NULL
)	NULL
,	NULL
pMAPK	NULL
(	NULL
at	NULL
~42	NULL
and	NULL
44	NULL
kDa	NULL
)	NULL
,	NULL
and	NULL
MAPK	NULL
(	NULL
at	NULL
~42	NULL
and	NULL
44	NULL
kDa	NULL
)	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

A	NULL
J77	NULL
JCaM1.6s.S3	NULL
o	NULL
86s	NULL
6	NULL
s	NULL
Jos	NULL
B	NULL
£	NULL
JL	NULL
s	NULL
s	NULL
&	NULL
cae	NULL
A	NULL
dll	NULL
wm	NULL
As	NULL
cae	NULL
Als	NULL
Juin	NULL
B	NULL
T	NULL
cells	NULL
,	NULL
__L_CeHs	NULL
&	NULL
o	NULL
<	NULL
=	NULL
8	NULL
&	NULL
aCD2	NULL
T	NULL
«	NULL
an	NULL
<	NULL
-ost-Jun	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

JNK	NULL
is	NULL
activated	NULL
in	NULL
JCaM1.6s.83	NULL
and	NULL
peripheral	NULL
T	NULL
cells	NULL
following	NULL
CD2	NULL
stimulation	NULL
.	NULL

J77	NULL
and	NULL
JCaM1.6s	NULL
.	NULL

$	NULL
3	NULL
cells	NULL
(	NULL
A	NULL
)	NULL
or	NULL
freshly	NULL
isolated	NULL
peripheral	NULL
T	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
were	NULL
either	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-T11	NULL
,	NULL
plus	NULL
anti-T11l	NULL
,	NULL
;	NULL
,	NULL
(	NULL
@	NULL
«	NULL
CD2	NULL
)	NULL
,	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
«	NULL
CD3	NULL
)	NULL
,	NULL
or	NULL
PMA	NULL
and	NULL
cell	NULL
lysates	NULL
were	NULL
immunoprecipitated	NULL
with	NULL
an	NULL
antiserum	NULL
specific	NULL
for	NULL
JNK	NULL
.	NULL

Subsequently	NULL
,	NULL
the	NULL
immunoprecipitates	NULL
were	NULL
subjected	NULL
to	NULL
an	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
GST-Jun	NULL
fusion	NULL
protein	NULL
as	NULL
a	NULL
substrate	NULL
and	NULL
analyzed	NULL
on	NULL
SDS-PAGE	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

The	NULL
migra-	NULL
tion	NULL
position	NULL
of	NULL
the	NULL
GST-Jun	NULL
fusion	NULL
protein	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

induced	NULL
JNK	NULL
activation	NULL
is	NULL
significantly	NULL
lower	NULL
than	NULL
CD2	NULL
induced	NULL
JNK	NULL
activation	NULL
in	NULL
JCaM1.6s.83	NULL
,	NULL
whereas	NULL
both	NULL
pathways	NULL
activate	NULL
JNK	NULL
in	NULL
J77	NULL
to	NULL
a	NULL
comparable	NULL
level	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

The	NULL
average	NULL
increase	NULL
of	NULL
JNK	NULL
activity	NULL
from	NULL
three	NULL
independent	NULL
experiments	NULL
following	NULL
CD2	NULL
or	NULL
CD3	NULL
stimulation	NULL
compared	NULL
with	NULL
unstimulated	NULL
cells	NULL
is	NULL
as	NULL
follows	NULL
:	NULL
JCaM1.6s.83	NULL
:	NULL
CD2	NULL
,	NULL
2.96	NULL
+	NULL
0.8	NULL
;	NULL
CD3	NULL
,	NULL
1.44	NULL
+	NULL
0.4	NULL
;	NULL
J77	NULL
:	NULL
CD2	NULL
,	NULL
1.54	NULL
+	NULL
0.2	NULL
;	NULL
CD8	NULL
,	NULL
1.72	NULL
+	NULL
0.5-fold	NULL
increase	NULL
(	NULL
over	NULL
background	NULL
unstimulated	NULL
controls	NULL
as	NULL
determined	NULL
by	NULL
scanning	NULL
the	NULL
autoradiographs	NULL
on	NULL
a	NULL
PhosphorImager	NULL
)	NULL
.	NULL

Following	NULL
CD2	NULL
Stimulation	NULL
There	NULL
Are	NULL
Predominantly	NULL
c-Jun/	NULL
c-Fos	NULL
Heterodimers	NULL
Binding	NULL
to	NULL
the	NULL
AP-1	NULL
Consensus	NULL
Site-The	NULL
IL-2	NULL
promoter	NULL
contains	NULL
several	NULL
binding	NULL
sites	NULL
for	NULL
transcription	NULL
factors	NULL
which	NULL
control	NULL
IL-2	NULL
gene	NULL
expression	NULL
including	NULL
AP-1	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
the	NULL
CD28RE	NULL
(	NULL
50	NULL
,	NULL
53	NULL
)	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
,	NULL
the	NULL
major	NULL
kinase	NULL
which	NULL
serine	NULL
phosphorylates	NULL
Jun	NULL
is	NULL
JNK	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Since	NULL
JNK	NULL
is	NULL
activated	NULL
in	NULL
JCaM1.6s.983	NULL
following	NULL
CD2	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
,	NULL
it	NULL
was	NULL
important	NULL
to	NULL
determine	NULL
how	NULL
this	NULL
activation	NULL
would	NULL
affect	NULL
AP-1	NULL
binding	NULL
.	NULL

As	NULL
shown	NULL
by	NULL
EMSA	NULL
(	NULL
elec-tromobility	NULL
shift	NULL
assay	NULL
)	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
,	NULL
compared	NULL
with	NULL
CD3	NULL
stimulation	NULL
,	NULL
the	NULL
CD2	NULL
induced	NULL
Jun	NULL
kinase	NULL
activity	NULL
in	NULL
JCaM1.6s.83	NULL
is	NULL
accompanied	NULL
by	NULL
enhanced	NULL
expression	NULL
and	NULL
binding	NULL
of	NULL
AP-1	NULL
complexes	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
.	NULL

This	NULL
interaction	NULL
of	NULL
AP-1	NULL
proteins	NULL
with	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
double-stranded	NULL
oligonucleotide	NULL
is	NULL
specific	NULL
for	NULL
AP-1	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
competition	NULL
experiments	NULL
using	NULL
an	NULL
excess	NULL
of	NULL
unlabeled	NULL
AP-1	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

In	NULL
J77	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
AP-1	NULL
complex	NULL
binding	NULL
is	NULL
similar	NULL
between	NULL
24253	NULL
CD2	NULL
and	NULL
CD3	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
complex	NULL
consists	NULL
of	NULL
homo-	NULL
or	NULL
heterodimers	NULL
of	NULL
proteins	NULL
of	NULL
the	NULL
Jun	NULL
and	NULL
Fos	NULL
family	NULL
(	NULL
54	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
Jun/Fos	NULL
heterodimers	NULL
have	NULL
a	NULL
higher	NULL
affinity	NULL
for	NULL
the	NULL
AP-1	NULL
site	NULL
and	NULL
are	NULL
more	NULL
efficient	NULL
in	NULL
activating	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
55	NULL
)	NULL
.	NULL

The	NULL
Jun	NULL
family	NULL
contains	NULL
at	NULL
least	NULL
three	NULL
members	NULL
,	NULL
c-Jun	NULL
,	NULL
JunB	NULL
,	NULL
and	NULL
JunD	NULL
,	NULL
while	NULL
the	NULL
Fos	NULL
family	NULL
includes	NULL
c-Fos	NULL
,	NULL
Fral	NULL
,	NULL
Fra2	NULL
,	NULL
and	NULL
FosB	NULL
(	NULL
51	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Following	NULL
CD2	NULL
stimulation	NULL
of	NULL
JCaM1.6s.83	NULL
both	NULL
homodimers	NULL
and	NULL
heterodimers	NULL
appear	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
as	NULL
shown	NULL
by	NULL
supershift	NULL
of	NULL
the	NULL
AP-1	NULL
proteins	NULL
with	NULL
the	NULL
respective	NULL
Abs	NULL
specific	NULL
for	NULL
JunD	NULL
,	NULL
c-Jun	NULL
,	NULL
and	NULL
c-Fos	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

These	NULL
AP-1	NULL
complexes	NULL
do	NULL
not	NULL
contain	NULL
JunB	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
Fral	NULL
,	NULL
Fra2	NULL
,	NULL
or	NULL
FosB	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
.	NULL

Given	NULL
that	NULL
the	NULL
supershift	NULL
with	NULL
anti-c-Jun	NULL
and	NULL
anti-c-Fos	NULL
Abs	NULL
results	NULL
in	NULL
a	NULL
mobility	NULL
shift	NULL
of	NULL
their	NULL
respective	NULL
complexes	NULL
to	NULL
the	NULL
same	NULL
position	NULL
in	NULL
the	NULL
gel	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
,	NULL
we	NULL
infer	NULL
that	NULL
c-Jun/c-Fos	NULL
heterodimers	NULL
are	NULL
formed	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
different	NULL
mobility	NULL
of	NULL
the	NULL
complex	NULL
in	NULL
the	NULL
supershift	NULL
with	NULL
anti-JunD	NULL
Ab	NULL
implies	NULL
that	NULL
JunD/JunD	NULL
homodimers	NULL
are	NULL
present	NULL
.	NULL

CD3	NULL
stimulation	NULL
is	NULL
less	NULL
efficient	NULL
in	NULL
AP-1	NULL
induction	NULL
in	NULL
JCaM1.6s.83	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
with	NULL
anti-CD2	NULL
stimulation	NULL
the	NULL
AP-1	NULL
complex	NULL
is	NULL
supershifted	NULL
to	NULL
the	NULL
greatest	NULL
extent	NULL
by	NULL
anti-c-Fos	NULL
mAb	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
with	NULL
anti-CD3	NULL
mAb	NULL
stimulation	NULL
anti-JunD	NULL
mAb	NULL
effects	NULL
the	NULL
greatest	NULL
shift	NULL
.	NULL

These	NULL
results	NULL
imply	NULL
that	NULL
the	NULL
AP-1	NULL
dimer	NULL
is	NULL
primarily	NULL
a	NULL
complex	NULL
consisting	NULL
of	NULL
JunD/JunD	NULL
homodimers	NULL
following	NULL
anti-CD3	NULL
stimulation	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

Although	NULL
not	NULL
shown	NULL
,	NULL
analysis	NULL
of	NULL
the	NULL
other	NULL
transcriptional	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
production	NULL
including	NULL
NF-AT	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
and	NULL
Oct-1	NULL
(	NULL
50	NULL
,	NULL
53	NULL
)	NULL
showed	NULL
similar	NULL
inducible	NULL
nuclear	NULL
protein	NULL
binding	NULL
profiles	NULL
to	NULL
the	NULL
NF-AT	NULL
,	NULL
NF-B	NULL
,	NULL
or	NULL
Oct-1	NULL
consensus	NULL
site	NULL
in	NULL
JCaM1.6s.83	NULL
following	NULL
CD2	NULL
or	NULL
CD3	NULL
trigger-ing	NULL
;	NULL
moreover	NULL
,	NULL
supershift	NULL
analysis	NULL
with	NULL
Abs	NULL
specific	NULL
for	NULL
c-Jun	NULL
,	NULL
JunD	NULL
,	NULL
or	NULL
c-Fos	NULL
revealed	NULL
no	NULL
difference	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
complex	NULL
binding	NULL
to	NULL
the	NULL
NF-AT	NULL
site	NULL
upon	NULL
either	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
stimulation	NULL
.	NULL

Similarly	NULL
,	NULL
Abs	NULL
specific	NULL
for	NULL
the	NULL
p50	NULL
or	NULL
p65	NULL
subunit	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
did	NULL
not	NULL
indicate	NULL
differential	NULL
effects	NULL
of	NULL
these	NULL
stimulatory	NULL
pathways	NULL
as	NULL
judged	NULL
by	NULL
supershift	NULL
analysis	NULL
of	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
NK-	NULL
«	NULL
B	NULL
consensus	NULL
site	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
if	NULL
resting	NULL
T	NULL
cells	NULL
would	NULL
respond	NULL
to	NULL
CD2	NULL
stimulation	NULL
similarly	NULL
in	NULL
terms	NULL
of	NULL
JNK	NULL
activation	NULL
and	NULL
binding	NULL
of	NULL
AP-1	NULL
proteins	NULL
,	NULL
we	NULL
performed	NULL
corresponding	NULL
experiments	NULL
in	NULL
freshly	NULL
isolated	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

JNK	NULL
is	NULL
activated	NULL
via	NULL
both	NULL
CD2	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
via	NULL
CD3	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
,	NULL
suggesting	NULL
,	NULL
as	NULL
discussed	NULL
below	NULL
,	NULL
an	NULL
important	NULL
role	NULL
for	NULL
the	NULL
CD2	NULL
signaling	NULL
pathway	NULL
in	NULL
T	NULL
cell	NULL
co-stimulation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
CD2	NULL
but	NULL
not	NULL
CD3	NULL
stimulation	NULL
also	NULL
efficiently	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
and	NULL
binding	NULL
of	NULL
AP-1	NULL
proteins	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

6C	NULL
)	NULL
.	NULL

The	NULL
Tyrosine	NULL
Kinase	NULL
Pyk2	NULL
Is	NULL
Activated	NULL
following	NULL
Stimulation	NULL
via	NULL
CD2	NULL
in	NULL
the	NULL
Absence	NULL
of	NULL
p56	NULL
``	NULL
**-Recently	NULL
,	NULL
Pyk2	NULL
a	NULL
tyrosine	NULL
kinase	NULL
homologous	NULL
to	NULL
the	NULL
focal	NULL
adhesion	NULL
kinase	NULL
(	NULL
FAK	NULL
)	NULL
has	NULL
been	NULL
identified	NULL
and	NULL
linked	NULL
to	NULL
the	NULL
JNK	NULL
pathway	NULL
,	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Pyk2	NULL
activation	NULL
,	NULL
like	NULL
JNK	NULL
activation	NULL
,	NULL
requires	NULL
a	NULL
strong	NULL
Ca**	NULL
signal	NULL
such	NULL
as	NULL
that	NULL
provided	NULL
by	NULL
CD2	NULL
stimulation	NULL
in	NULL
JCaM1L.6s.53	NULL
.	NULL

We	NULL
investigated	NULL
the	NULL
activation	NULL
of	NULL
Pyk2	NULL
in	NULL
JeaM1.6s.83	NULL
following	NULL
anti-CD2	NULL
or	NULL
anti-CD3	NULL
mAb	NULL
triggering	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
and	NULL
in	NULL
vitro	NULL
kinase	NULL
assay	NULL
.	NULL

Pyk2	NULL
is	NULL
phosphorylated	NULL
in	NULL
response	NULL
to	NULL
both	NULL
CD2	NULL
and	NULL
CD3	NULL
triggering	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
,	NULL
but	NULL
activated	NULL
only	NULL
after	NULL
CD2	NULL
stimulation	NULL
as	NULL
judged	NULL
by	NULL
in	NULL
vitro	NULL
autophosphorylation	NULL
(	NULL
Fig	NULL
.	NULL

8C	NULL
)	NULL
.	NULL

Equivalent	NULL
amounts	NULL
of	NULL
Pyk2	NULL
were	NULL
precipitated	NULL
as	NULL
shown	NULL
by	NULL
sequential	NULL
immunoblotting	NULL
of	NULL
the	NULL
phosphotyrosine	NULL
blot	NULL
(	NULL
Fig	NULL
.	NULL

84	NULL
)	NULL
with	NULL
a	NULL
Pyk2-specific	NULL
rabbit	NULL
antiserum	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

DISCUSSION	NULL
In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
identify	NULL
a	NULL
CD2	NULL
signaling	NULL
pathway	NULL
capable	NULL
of	NULL
inducing	NULL
IL-2	NULL
production	NULL
.	NULL

Fig	NULL
.	NULL

9	NULL
offers	NULL
a	NULL
schematic	NULL
view	NULL
of	NULL
p56	NULL
``	NULL
**-independent	NULL
as	NULL
well	NULL
as	NULL
-dependent	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
24254	NULL
A	NULL
AP-1	NULL
J77	NULL
I	NULL
n	NULL
oa	NULL
c	NULL
&	NULL
o	NULL
co	NULL
©	NULL
-	NULL
w	NULL
f	NULL
O	NULL
L3	NULL
B86	NULL
8	NULL
L	NULL
§	NULL
%	NULL
&	NULL
%	NULL
f	NULL
Wii	NULL
Whig	NULL
.	NULL

-	NULL
>	NULL
>	NULL
bad	NULL
tatu	NULL
tut	NULL
anc	NULL
ith	NULL
dll	NULL
!	NULL

-	NULL
(	NULL
:	NULL
oligo	NULL
B	NULL
AP-1	NULL
JCaM1.6s	NULL
.	NULL

$	NULL
3	NULL
(	NULL
-	NULL
)	NULL
aCD2	NULL
aCD3	NULL
m-	NULL
+	NULL
al	NULL
100xNF-AT	NULL
100xNF-AT	NULL
(	NULL
-	NULL
]	NULL
1	NULL
100xNF-AT	NULL
(	NULL
-	NULL
]	NULL
100xAP-1	NULL
(	NULL
-	NULL
)	NULL
100xAP-1	NULL
<	NULL
-AP-1	NULL
®	NULL
wo	NULL
=	NULL
__	NULL
Free	NULL
oligo	NULL
AP-1	NULL
T	NULL
cells	NULL
m	NULL
a	NULL
o	NULL
©	NULL
w	NULL
-	NULL
,	NULL
A	NULL
a	NULL
©	NULL
Z	NULL
|	NULL
O	NULL
O	NULL
Z	NULL
«	NULL
~	NULL
o	NULL
w	NULL
3	NULL
3	NULL
a	NULL
<	NULL
C	NULL
<	NULL
-	NULL
AP-	NULL
4	NULL
__Free	NULL
oligo	NULL
Fic	NULL
.	NULL

6	NULL
.	NULL

Analysis	NULL
of	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
in	NULL
J77	NULL
and	NULL
JCaM1.6	NULL
s.83	NULL
(	NULL
A	NULL
and	NULL
B	NULL
)	NULL
or	NULL
peripheral	NULL
T	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
CD2	NULL
activation	NULL
pathways	NULL
(	NULL
87	NULL
,	NULL
39	NULL
,	NULL
56	NULL
,	NULL
57	NULL
)	NULL
.	NULL

The	NULL
latter	NULL
is	NULL
largely	NULL
indistinguishable	NULL
from	NULL
the	NULL
p56	NULL
``	NULL
**-dependent	NULL
TCR	NULL
pathway	NULL
except	NULL
that	NULL
,	NULL
unlike	NULL
the	NULL
TCR	NULL
pathway	NULL
,	NULL
it	NULL
is	NULL
associated	NULL
with	NULL
weak	NULL
CD37	NULL
and	NULL
ZAPT7O0	NULL
phosphorylation	NULL
.	NULL

In	NULL
JCaM1.6	NULL
cells	NULL
,	NULL
only	NULL
the	NULL
p56	NULL
``	NULL
*-independent	NULL
CD2	NULL
pathway	NULL
is	NULL
operative	NULL
and	NULL
,	NULL
in	NULL
distinction	NULL
to	NULL
the	NULL
TCR	NULL
pathway	NULL
,	NULL
does	NULL
not	NULL
involve	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
ZAP70	NULL
,	NULL
or	NULL
MAPK	NULL
.	NULL

Instead	NULL
,	NULL
CD2	NULL
triggering	NULL
activates	NULL
JNK	NULL
followed	NULL
by	NULL
the	NULL
binding	NULL
of	NULL
c-Jun/c-Fos	NULL
heterodimers	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
.	NULL

Prior	NULL
studies	NULL
of	NULL
TCR-based	NULL
signaling	NULL
showed	NULL
that	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
TCR	NULL
triggered	NULL
signals	NULL
were	NULL
abrogated	NULL
(	NULL
42	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
as	NULL
shown	NULL
here	NULL
,	NULL
activation	NULL
via	NULL
CD2	NULL
in	NULL
the	NULL
p56	NULL
``	NULL
**-deficient	NULL
Jurkat	NULL
variant	NULL
JCaM1.6s	NULL
is	NULL
not	NULL
disrupted	NULL
.	NULL

CD2	NULL
stimulation	NULL
leads	NULL
to	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
PLC-y1	NULL
,	NULL
a	NULL
strong	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
levels	NULL
,	NULL
and	NULL
subsequent	NULL
production	NULL
of	NULL
IL-2	NULL
.	NULL

Furthermore	NULL
,	NULL
CD2	NULL
signaling	NULL
stimulates	NULL
JNK	NULL
,	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
factors	NULL
of	NULL
the	NULL
Jun	NULL
family	NULL
.	NULL

Phosphorylated	NULL
c-Jun/c-Fos	NULL
heterodimers	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
transcription	NULL
.	NULL

Although	NULL
CD2	NULL
signaling	NULL
in	NULL
T	NULL
cells	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
CD3Z	NULL
chain	NULL
(	NULL
27-31	NULL
)	NULL
,	NULL
the	NULL
precise	NULL
molecular	NULL
basis	NULL
by	NULL
which	NULL
cell	NULL
surface	NULL
immunoreceptor	NULL
tyrosine-based	NULL
activation	NULL
motif	NULL
containing	NULL
TCR	NULL
subunits	NULL
permit	NULL
CD2	NULL
signaling	NULL
remains	NULL
uncer-tain	NULL
.	NULL

The	NULL
functional	NULL
involvement	NULL
of	NULL
the	NULL
CD34	NULL
chain	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
stimulation	NULL
of	NULL
phosphatidylinositol	NULL
turnover	NULL
(	NULL
46	NULL
,	NULL
58	NULL
)	NULL
shared	NULL
by	NULL
TCR	NULL
and	NULL
CD2	NULL
pathways	NULL
indicates	NULL
the	NULL
usage	NULL
of	NULL
a	NULL
common	NULL
pathway	NULL
following	NULL
CD2	NULL
and	NULL
TCR	NULL
signaling	NULL
.	NULL

Indeed	NULL
,	NULL
a	NULL
complex	NULL
involving	NULL
CD2	NULL
,	NULL
p59	NULL
``	NULL
,	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
exist	NULL
in	NULL
T	NULL
lymphocytes	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
certain	NULL
differences	NULL
among	NULL
the	NULL
pathways	NULL
are	NULL
also	NULL
evident	NULL
.	NULL

For	NULL
example	NULL
,	NULL
T	NULL
cell	NULL
activation	NULL
via	NULL
CD2	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
via	NULL
the	NULL
TCR	NULL
,	NULL
is	NULL
not	NULL
associated	NULL
with	NULL
Syk	NULL
phosphorylation	NULL
and	NULL
involves	NULL
minimal	NULL
if	NULL
any	NULL
phosphorylation	NULL
of	NULL
ZAP-70	NULL
or	NULL
CD3	NULL
(	NULL
25	NULL
,	NULL
27	NULL
,	NULL
59	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
the	NULL
phosphorylation	NULL
kinetics	NULL
and	NULL
cellular	NULL
substrates	NULL
are	NULL
distinct	NULL
in	NULL
these	NULL
two	NULL
pathways	NULL
(	NULL
25	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
Tec	NULL
family	NULL
kinase	NULL
ITK	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
activated	NULL
upon	NULL
stimulation	NULL
via	NULL
CD2	NULL
(	NULL
60	NULL
)	NULL
.	NULL

This	NULL
ITK	NULL
activation	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
functional	NULL
p56	NULL
``	NULL
but	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CDSL	NULL
(	NULL
60	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
CD2	NULL
plays	NULL
important	NULL
roles	NULL
in	NULL
reversing	NULL
anergy	NULL
and	NULL
augmenting	NULL
IL-12	NULL
responsiveness	NULL
;	NULL
neither	NULL
activities	NULL
are	NULL
TCR	NULL
regulated	NULL
(	NULL
15	NULL
,	NULL
17	NULL
)	NULL
.	NULL

CD2	NULL
signaling	NULL
is	NULL
mediated	NULL
by	NULL
its	NULL
proline-rich	NULL
intracytoplasmic	NULL
domain	NULL
to	NULL
which	NULL
SH3	NULL
domains	NULL
of	NULL
non-receptor	NULL
kinases	NULL
can	NULL
bind	NULL
(	NULL
23	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
indicate	NULL
that	NULL
p56	NULL
``	NULL
**	NULL
and	NULL
p59	NULL
``	NULL
are	NULL
able	NULL
to	NULL
bind	NULL
to	NULL
CD2	NULL
and	NULL
hence	NULL
are	NULL
implicated	NULL
in	NULL
CD2	NULL
signaling	NULL
(	NULL
84	NULL
,	NULL
35	NULL
,	NULL
61	NULL
)	NULL
.	NULL

p56	NULL
``	NULL
**	NULL
is	NULL
present	NULL
in	NULL
thymocytes	NULL
and	NULL
mature	NULL
T	NULL
cells	NULL
and	NULL
is	NULL
involved	NULL
in	NULL
signaling	NULL
via	NULL
the	NULL
TCR	NULL
(	NULL
62	NULL
)	NULL
.	NULL

T	NULL
cells	NULL
from	NULL
mice	NULL
bearing	NULL
a	NULL
disrupted	NULL
p56	NULL
``	NULL
gene	NULL
(	NULL
63	NULL
)	NULL
,	NULL
mutant	NULL
Jurkat	NULL
cells	NULL
lacking	NULL
functional	NULL
p56hk	NULL
(	NULL
JCaM1I.6	NULL
)	NULL
(	NULL
42	NULL
)	NULL
,	NULL
or	NULL
CTLL-2	NULL
cells	NULL
that	NULL
lack	NULL
p56	NULL
``	NULL
expression	NULL
show	NULL
defects	NULL
in	NULL
TCR-mediated	NULL
responses	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Upon	NULL
TCR	NULL
stimulation	NULL
p56	NULL
``	NULL
*	NULL
associates	NULL
with	NULL
and	NULL
phosphorylates	NULL
ZAPT7O	NULL
and	NULL
it	NULL
has	NULL
been	NULL
speculated	NULL
that	NULL
ZAPT7O	NULL
may	NULL
,	NULL
therefore	NULL
be	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
responsible	NULL
for	NULL
bringing	NULL
p56'**	NULL
into	NULL
the	NULL
signaling	NULL
complex	NULL
(	NULL
64	NULL
,	NULL
65	NULL
)	NULL
.	NULL

Notwithstanding	NULL
,	NULL
other	NULL
experiments	NULL
employing	NULL
mutant	NULL
immunoreceptor	NULL
tyrosine-based	NULL
activation	NULL
motif	NULL
sequences	NULL
demonstrate	NULL
that	NULL
p56	NULL
``	NULL
**	NULL
can	NULL
cells	NULL
(	NULL
C	NULL
)	NULL
.	NULL

A	NULL
,	NULL
nuclear	NULL
extracts	NULL
of	NULL
J77	NULL
and	NULL
JCaM1.6	NULL
s.88	NULL
cells	NULL
either	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-Tll	NULL
,	NULL
plus	NULL
anti-T1l1	NULL
,	NULL
(	NULL
aCD2	NULL
)	NULL
or	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
«	NULL
CD8	NULL
)	NULL
were	NULL
subjected	NULL
to	NULL
EMSAs	NULL
with	NULL
[	NULL
y-	NULL
``	NULL
°P	NULL
]	NULL
IATP-labeled	NULL
oligonucleotides	NULL
specific	NULL
for	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
.	NULL

B	NULL
,	NULL
further	NULL
analysis	NULL
of	NULL
JCaM1.6s.53	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
either	NULL
a	NULL
specific	NULL
(	NULL
100-fold	NULL
AP-1	NULL
)	NULL
or	NULL
a	NULL
nonspecific	NULL
(	NULL
100-fold	NULL
NF-AT	NULL
)	NULL
unlabeled	NULL
competitor	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
analyzed	NULL
on	NULL
5.2	NULL
%	NULL
gels	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

The	NULL
migration	NULL
position	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
(	NULL
arrow	NULL
)	NULL
and	NULL
the	NULL
free	NULL
oligo	NULL
are	NULL
indicated	NULL
.	NULL

C	NULL
,	NULL
equivalent	NULL
EMSA	NULL
analysis	NULL
from	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
AP-1	NULL
JCaM1.6s.S83	NULL
I	NULL
1	NULL
(	NULL
-	NULL
)	NULL
a	NULL
CD2	NULL
a	NULL
CD3	NULL
I	NULL
W	NULL
h	NULL
1	NULL
&	NULL
a	NULL
c	NULL
a	NULL
[	NULL
=	NULL
w	NULL
LW	NULL
as	NULL
§	NULL
6,5	NULL
§	NULL
¢	NULL
T	NULL
_	NULL
0	NULL
``	NULL
o	NULL
_	NULL
0	NULL
~	NULL
g	NULL
_	NULL
0	NULL
~	NULL
o	NULL
C	NULL
=	NULL
--	NULL
JunD	NULL
<	NULL
-	NULL
c-Jun/c-Fos	NULL
#	NULL
“	NULL
ﬂaw	NULL
“	NULL
a-	NULL
»	NULL
P	NULL
Wis	NULL
®	NULL
A	NULL
mame	NULL
-	NULL
Free	NULL
oligo	NULL
AP-1	NULL
JCaM1.6s	NULL
.	NULL

$	NULL
3	NULL
I	NULL
I	NULL
(	NULL
-	NULL
)	NULL
aCD2	NULL
aCD3	NULL
I	NULL
m	NULL
”	NULL
1	NULL
1	NULL
~	NULL
BR	NULL
qld	NULL
wo	NULL
lL	NULL
lE	NULL
IL	NULL
G	NULL
wo	NULL
E	NULL
L	NULL
K	NULL
G	NULL
wo	NULL
IL	NULL
Ho	NULL
lL	NULL
O	NULL
L	NULL
4	NULL
<	NULL
-wo	NULL
t	NULL
wns	NULL
we	NULL
som	NULL
Oh	NULL
Au	NULL
donk	NULL
Ohh	NULL
toe	NULL
tand	NULL
taut	NULL
th	NULL
taut	NULL
ts	NULL
-	NULL
A-	NULL
1	NULL
Laik	NULL
4	NULL
ath	NULL
,	NULL
_	NULL
Free	NULL
oligo	NULL
Fic	NULL
.	NULL

7	NULL
.	NULL

Supershift	NULL
analysis	NULL
of	NULL
nuclear	NULL
proteins	NULL
of	NULL
JCaM1.6s.83	NULL
binding	NULL
to	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
.	NULL

JCaM1.6s.53	NULL
cells	NULL
were	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-Tl1	NULL
,	NULL
plus	NULL
anti-T11l	NULL
,	NULL
(	NULL
aCD2	NULL
)	NULL
or	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
aCD3	NULL
)	NULL
and	NULL
nuclear	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
EMSAs	NULL
with	NULL
labeled	NULL
oligonucleotides	NULL
specific	NULL
for	NULL
the	NULL
AP-1	NULL
consensus	NULL
site	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Abs	NULL
specific	NULL
for	NULL
members	NULL
of	NULL
the	NULL
Jun	NULL
family	NULL
(	NULL
A	NULL
)	NULL
or	NULL
the	NULL
Fos	NULL
family	NULL
(	NULL
B	NULL
)	NULL
.	NULL

The	NULL
complexes	NULL
were	NULL
analyzed	NULL
on	NULL
4	NULL
%	NULL
gels	NULL
followed	NULL
by	NULL
autoradiography	NULL
.	NULL

The	NULL
migration	NULL
position	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
,	NULL
the	NULL
supershifted	NULL
complexes	NULL
and	NULL
the	NULL
free	NULL
oligo	NULL
are	NULL
indicated	NULL
by	NULL
arrows	NULL
.	NULL

associate	NULL
with	NULL
the	NULL
TCR	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
ZAPT7O	NULL
(	NULL
66	NULL
)	NULL
.	NULL

Nevertheless	NULL
,	NULL
p56	NULL
``	NULL
is	NULL
thought	NULL
to	NULL
be	NULL
responsible	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
ZAPT7O0	NULL
enzymatic	NULL
function	NULL
(	NULL
48	NULL
,	NULL
65	NULL
)	NULL
.	NULL

The	NULL
tyrosine	NULL
kinase	NULL
ZAP70	NULL
is	NULL
a	NULL
key	NULL
molecule	NULL
in	NULL
TCR	NULL
signaling	NULL
,	NULL
but	NULL
can	NULL
in	NULL
some	NULL
systems	NULL
be	NULL
replaced	NULL
by	NULL
p72	NULL
Syk	NULL
(	NULL
67	NULL
,	NULL
68	NULL
)	NULL
.	NULL

We	NULL
and	NULL
others	NULL
(	NULL
25	NULL
,	NULL
59	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
following	NULL
CD2	NULL
stimulation	NULL
ZAP70	NULL
is	NULL
only	NULL
weakly	NULL
if	NULL
at	NULL
all	NULL
tyrosine	NULL
phosphorylated	NULL
or	NULL
activated	NULL
in	NULL
J77	NULL
.	NULL

In	NULL
JCaM1.6s	NULL
no	NULL
tyrosine	NULL
phosphorylation	NULL
or	NULL
activation	NULL
of	NULL
ZAPT7O0	NULL
after	NULL
either	NULL
CD2	NULL
or	NULL
CD3	NULL
triggering	NULL
was	NULL
24255	NULL
JCaM1.6s.S3	NULL
[	NULL
ad	NULL
co	NULL
o	NULL
a	NULL
1T	NULL
Q	NULL
Q	NULL
e	NULL
Y	NULL
&	NULL
A	NULL
Pyk2	NULL
-	NULL
»	NULL
y-	NULL
«	NULL
s	NULL
we	NULL
apTyr	NULL
WB	NULL
B	NULL
pyro	NULL
»	NULL
4	NULL
wit	NULL
dee	NULL
oPyk2	NULL
}	NULL
w	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Pyk2	NULL
is	NULL
activated	NULL
following	NULL
CD2	NULL
stimulation	NULL
.	NULL

JCaM1.6s.93	NULL
cells	NULL
,	NULL
either	NULL
unstimulated	NULL
(	NULL
-	NULL
)	NULL
or	NULL
stimulated	NULL
for	NULL
3	NULL
min	NULL
with	NULL
either	NULL
a	NULL
combination	NULL
of	NULL
the	NULL
anti-CD2	NULL
mAbs	NULL
anti-Tl1l	NULL
,	NULL
plus	NULL
anti-Tl1	NULL
;	NULL
(	NULL
aCD2	NULL
)	NULL
or	NULL
the	NULL
anti-CD8e	NULL
mAb	NULL
2AD2A2	NULL
(	NULL
@	NULL
CD3	NULL
)	NULL
.	NULL

Cell	NULL
lysates	NULL
were	NULL
im-munoprecipitaed	NULL
with	NULL
Pyk2	NULL
Ab	NULL
and	NULL
were	NULL
either	NULL
subjected	NULL
to	NULL
sequential	NULL
Western	NULL
blot	NULL
analysis	NULL
with	NULL
anti-phosphotyrosine-specific	NULL
mAb	NULL
4G10	NULL
(	NULL
A	NULL
)	NULL
and	NULL
an	NULL
antiserum	NULL
specific	NULL
for	NULL
Pyk2	NULL
(	NULL
B	NULL
)	NULL
or	NULL
to	NULL
in	NULL
vitro	NULL
kinase	NULL
analysis	NULL
(	NULL
C	NULL
)	NULL
.	NULL

The	NULL
position	NULL
of	NULL
Pyk2	NULL
at	NULL
~120	NULL
kDa	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

C	NULL
Pyk2	NULL
-	NULL
»	NULL
som	NULL
dlt	NULL
ms	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
JCaM1.6	NULL
and	NULL
its	NULL
parental	NULL
Jurkat	NULL
line	NULL
E6	NULL
are	NULL
deficient	NULL
in	NULL
Syk	NULL
expression	NULL
(	NULL
69	NULL
)	NULL
and	NULL
there	NULL
is	NULL
no	NULL
evidence	NULL
for	NULL
the	NULL
presence	NULL
or	NULL
phosphorylation	NULL
of	NULL
Syk	NULL
in	NULL
JCaM1L.6s	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
,	NULL
therefore	NULL
,	NULL
conclude	NULL
that	NULL
in	NULL
JCaM1.6s	NULL
,	NULL
CD2-triggered	NULL
IL-2	NULL
production	NULL
does	NULL
not	NULL
involve	NULL
tyrosine	NULL
kinases	NULL
of	NULL
the	NULL
Syk	NULL
family	NULL
.	NULL

Events	NULL
downstream	NULL
of	NULL
protein-tyrosine	NULL
kinase	NULL
activation	NULL
include	NULL
the	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
activation	NULL
of	NULL
PLC-y1	NULL
,	NULL
which	NULL
then	NULL
leads	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
concentrations	NULL
via	NULL
the	NULL
generation	NULL
of	NULL
inositol	NULL
trisphosphate	NULL
(	NULL
70	NULL
)	NULL
.	NULL

In	NULL
p56**	NULL
expressing	NULL
T	NULL
cells	NULL
,	NULL
TCR	NULL
stimulation	NULL
is	NULL
followed	NULL
by	NULL
an	NULL
initial	NULL
high	NULL
transient	NULL
Ca**	NULL
``	NULL
peak	NULL
and	NULL
a	NULL
lower	NULL
amplitude	NULL
but	NULL
sustained	NULL
plateau	NULL
phase	NULL
(	NULL
41	NULL
,	NULL
44	NULL
,	NULL
46	NULL
)	NULL
.	NULL

The	NULL
initial	NULL
rise	NULL
of	NULL
Ca**	NULL
is	NULL
caused	NULL
by	NULL
the	NULL
inositol	NULL
trisphosphate-mediated	NULL
release	NULL
of	NULL
Ca**	NULL
from	NULL
the	NULL
endoplasmatic	NULL
reticulum	NULL
(	NULL
45	NULL
)	NULL
but	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
proliferation	NULL
or	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
41	NULL
,	NULL
71	NULL
)	NULL
.	NULL

Rather	NULL
the	NULL
prolonged	NULL
elevation	NULL
of	NULL
intracellular	NULL
Ca*	NULL
``	NULL
*	NULL
due	NULL
to	NULL
the	NULL
Ca**	NULL
influx	NULL
from	NULL
extracellular	NULL
sources	NULL
is	NULL
the	NULL
critical	NULL
component	NULL
of	NULL
the	NULL
Ca**	NULL
signal	NULL
(	NULL
41	NULL
,	NULL
71	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
Ca**	NULL
enters	NULL
T	NULL
cells	NULL
from	NULL
extracellular	NULL
stores	NULL
in	NULL
not	NULL
well	NULL
understood	NULL
(	NULL
72	NULL
)	NULL
.	NULL

However	NULL
,	NULL
in	NULL
JCaM1.6s	NULL
,	NULL
anti-CD3	NULL
stimulation	NULL
leads	NULL
only	NULL
to	NULL
a	NULL
short	NULL
duration	NULL
Ca**	NULL
increase	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
a	NULL
sustained	NULL
high	NULL
Ca**	NULL
rise	NULL
,	NULL
suggesting	NULL
that	NULL
p56	NULL
``	NULL
*	NULL
is	NULL
involved	NULL
,	NULL
either	NULL
directly	NULL
or	NULL
indirectly	NULL
,	NULL
in	NULL
TCR-mediated	NULL
Ca**	NULL
influx	NULL
from	NULL
extracellular	NULL
stores	NULL
.	NULL

Inositol	NULL
trisphosphate	NULL
is	NULL
generated	NULL
by	NULL
hydrolysis	NULL
of	NULL
phosphatidylinositol	NULL
bisphosphate	NULL
by	NULL
PLC-y1	NULL
.	NULL

As	NULL
reported	NULL
previously	NULL
,	NULL
JCaM1.6	NULL
cells	NULL
fail	NULL
to	NULL
show	NULL
production	NULL
of	NULL
inositol	NULL
phosphates	NULL
after	NULL
TCR	NULL
triggering	NULL
(	NULL
73	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
finding	NULL
,	NULL
PLC-y1	NULL
,	NULL
whose	NULL
catalytic	NULL
activity	NULL
is	NULL
strongly	NULL
enhanced	NULL
by	NULL
tyrosine	NULL
phosphorylation	NULL
(	NULL
74	NULL
)	NULL
,	NULL
is	NULL
only	NULL
weakly	NULL
phosphorylated	NULL
upon	NULL
TCR	NULL
triggering	NULL
in	NULL
JCaM1L.6s	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
CD3	NULL
stimulation	NULL
,	NULL
CD2	NULL
stimulation	NULL
leads	NULL
to	NULL
a	NULL
clear	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
PLC-y1	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
and	NULL
to	NULL
a	NULL
strong	NULL
and	NULL
long	NULL
lasting	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
levels	NULL
in	NULL
JCaM1.6s	NULL
(	NULL
Fig	NULL
.	NULL

24	NULL
)	NULL
.	NULL

Although	NULL
Hubert	NULL
et	NULL
al	NULL
.	NULL

(	NULL
59	NULL
)	NULL
failed	NULL
to	NULL
detect	NULL
anti-CD2	NULL
mAb	NULL
induced	NULL
PLCy	NULL
phosphorylation	NULL
in	NULL
JCaM1	NULL
cells	NULL
,	NULL
a	NULL
difference	NULL
in	NULL
the	NULL
surface	NULL
expression	NULL
of	NULL
CD3	NULL
and	NULL
CD2	NULL
on	NULL
JCaM1	NULL
versus	NULL
the	NULL
sorted	NULL
JCaM1.6s	NULL
cells	NULL
herein	NULL
may	NULL
explain	NULL
this	NULL
discrepancy	NULL
.	NULL

TCR	NULL
stimulation	NULL
events	NULL
downstream	NULL
of	NULL
ZAP7O0	NULL
include	NULL
She	NULL
phosphorylation	NULL
,	NULL
the	NULL
activation	NULL
of	NULL
Sos	NULL
,	NULL
and	NULL
subsequently	NULL
of	NULL
Ras	NULL
leading	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
MAPK	NULL
pathway	NULL
and	NULL
finally	NULL
to	NULL
IL-2	NULL
production	NULL
(	NULL
56	NULL
)	NULL
.	NULL

This	NULL
tyrosine	NULL
kinase	NULL
activation	NULL
following	NULL
TCR	NULL
engagement	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
functional	NULL
p56	NULL
``	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
therefore	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
although	NULL
the	NULL
MAPK	NULL
pathway	NULL
is	NULL
non-functional	NULL
after	NULL
CD2	NULL
stimulation	NULL
as	NULL
well	NULL
as	NULL
CD3	NULL
stimulation	NULL
in	NULL
JCaM1.6s.83	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
CD2	NULL
mAbs	NULL
to	NULL
induce	NULL
IL-2	NULL
produc-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
24256	NULL
Fic	NULL
.	NULL

9	NULL
.	NULL

Signal	NULL
transduction	NULL
via	NULL
CD2	NULL
.	NULL

p56	NULL
``	NULL
**-dependent	NULL
and	NULL
independent	NULL
activation	NULL
pathways	NULL
following	NULL
CD2	NULL
stimulation	NULL
are	NULL
based	NULL
on	NULL
prior	NULL
results	NULL
(	NULL
87	NULL
,	NULL
39	NULL
,	NULL
56	NULL
,	NULL
57	NULL
,	NULL
75	NULL
)	NULL
and	NULL
the	NULL
current	NULL
studies	NULL
.	NULL

In	NULL
JCaM1L.6	NULL
,	NULL
only	NULL
the	NULL
p56**	NULL
independent	NULL
signal	NULL
transduction	NULL
pathway	NULL
is	NULL
functional	NULL
leading	NULL
via	NULL
JNK	NULL
and	NULL
subsequent	NULL
c-Jun	NULL
activation	NULL
to	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
the	NULL
initiation	NULL
of	NULL
IL-2	NULL
transcription	NULL
.	NULL

Both	NULL
pathways	NULL
apparently	NULL
activate	NULL
PLC-y1	NULL
leading	NULL
to	NULL
the	NULL
generation	NULL
of	NULL
a	NULL
rise	NULL
in	NULL
intracellular	NULL
free	NULL
Ca**	NULL
,	NULL
resulting	NULL
in	NULL
a	NULL
calmodulin-dependent	NULL
activation	NULL
of	NULL
calcineurin	NULL
.	NULL

The	NULL
latter	NULL
dephosphory-lates	NULL
NF-AT	NULL
resulting	NULL
in	NULL
its	NULL
nuclear	NULL
translocation	NULL
.	NULL

tion	NULL
was	NULL
not	NULL
compromised	NULL
.	NULL

These	NULL
observations	NULL
strongly	NULL
indicate	NULL
that	NULL
CD2	NULL
stimulation	NULL
can	NULL
activate	NULL
signaling	NULL
pathways	NULL
distinct	NULL
from	NULL
CD3	NULL
stimulation	NULL
.	NULL

Pyk2	NULL
was	NULL
recently	NULL
identified	NULL
as	NULL
a	NULL
tyrosine	NULL
kinase	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
Jun	NULL
kinase	NULL
activation	NULL
and	NULL
associates	NULL
with	NULL
the	NULL
adapter	NULL
protein	NULL
Grb2	NULL
(	NULL
39	NULL
)	NULL
.	NULL

By	NULL
forming	NULL
a	NULL
complex	NULL
containing	NULL
Pyk2	NULL
and	NULL
the	NULL
GDP-GTP	NULL
exchange	NULL
factor	NULL
Vav	NULL
(	NULL
75	NULL
)	NULL
,	NULL
Grb2	NULL
can	NULL
link	NULL
Pyk2	NULL
to	NULL
the	NULL
GTP-binding	NULL
protein	NULL
Rac	NULL
,	NULL
whose	NULL
activation	NULL
finally	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
JNK	NULL
(	NULL
57	NULL
)	NULL
.	NULL

In	NULL
our	NULL
study	NULL
,	NULL
we	NULL
show	NULL
that	NULL
,	NULL
following	NULL
both	NULL
CD2	NULL
and	NULL
CD3	NULL
stimulation	NULL
,	NULL
Pyk2	NULL
is	NULL
tyrosine	NULL
phosphorylated	NULL
in	NULL
JCaM1.6s.83	NULL
cells	NULL
,	NULL
but	NULL
only	NULL
CD2	NULL
triggering	NULL
activates	NULL
Pyk2	NULL
enzymatically	NULL
,	NULL
providing	NULL
a	NULL
possible	NULL
link	NULL
to	NULL
a	NULL
stimulation	NULL
pathway	NULL
which	NULL
leads	NULL
to	NULL
JNK	NULL
activation	NULL
.	NULL

JNK	NULL
is	NULL
important	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
since	NULL
JNK	NULL
activation	NULL
correlates	NULL
with	NULL
IL-2	NULL
production	NULL
(	NULL
88	NULL
,	NULL
51	NULL
,	NULL
52	NULL
,	NULL
76	NULL
)	NULL
.	NULL

IL-2	NULL
promoter	NULL
regulation	NULL
involves	NULL
several	NULL
transcription	NULL
factors	NULL
some	NULL
of	NULL
which	NULL
are	NULL
JNK	NULL
sensitive	NULL
(	NULL
50	NULL
,	NULL
51	NULL
,	NULL
77-80	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
transcription	NULL
factor	NULL
can	NULL
bind	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
either	NULL
directly	NULL
at	NULL
the	NULL
AP-1	NULL
site	NULL
(	NULL
81	NULL
,	NULL
82	NULL
)	NULL
or	NULL
together	NULL
with	NULL
NF-AT	NULL
or	NULL
Oct	NULL
at	NULL
their	NULL
respective	NULL
binding	NULL
sites	NULL
(	NULL
83-86	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
complex	NULL
is	NULL
composed	NULL
of	NULL
proteins	NULL
of	NULL
the	NULL
Jun	NULL
and	NULL
Fos	NULL
family	NULL
(	NULL
51	NULL
)	NULL
.	NULL

JNK	NULL
,	NULL
a	NULL
Ca*	NULL
``	NULL
*-sensitive	NULL
serine/threonine	NULL
kinase	NULL
of	NULL
the	NULL
MAP	NULL
kinase	NULL
fam-ily	NULL
,	NULL
is	NULL
critically	NULL
involved	NULL
in	NULL
the	NULL
post-transcriptional	NULL
stimulation	NULL
of	NULL
AP-1	NULL
activity	NULL
by	NULL
phosphorylating	NULL
the	NULL
activation	NULL
domain	NULL
of	NULL
c-Jun	NULL
.	NULL

Su	NULL
et	NULL
al	NULL
.	NULL

(	NULL
38	NULL
)	NULL
reported	NULL
that	NULL
two	NULL
signals	NULL
are	NULL
necessary	NULL
to	NULL
efficiently	NULL
activate	NULL
JNK	NULL
,	NULL
including	NULL
different	NULL
combinations	NULL
of	NULL
A23187	NULL
,	NULL
TPA	NULL
,	NULL
anti-CD3	NULL
mAb	NULL
,	NULL
or	NULL
anti-CD28	NULL
mAb	NULL
.	NULL

This	NULL
dual	NULL
activation	NULL
requirement	NULL
and	NULL
the	NULL
reported	NULL
Ca**	NULL
sensitivity	NULL
distinguishes	NULL
JNK	NULL
from	NULL
other	NULL
members	NULL
of	NULL
the	NULL
MAPK/JNK	NULL
family	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
CD2	NULL
stimulation	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
JNK	NULL
has	NULL
not	NULL
yet	NULL
been	NULL
previously	NULL
investigated	NULL
.	NULL

In	NULL
both	NULL
J77	NULL
and	NULL
JCaM1.6s.983	NULL
,	NULL
JNK	NULL
is	NULL
activated	NULL
following	NULL
stimulation	NULL
via	NULL
CD2	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
CD2	NULL
utilizes	NULL
a	NULL
p56**	NULL
independent	NULL
pathway	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
JNK	NULL
.	NULL

The	NULL
strong	NULL
and	NULL
long	NULL
lasting	NULL
Ca**	NULL
mobilization	NULL
observed	NULL
in	NULL
JCaM1.6s.83	NULL
following	NULL
CD2	NULL
stimulation	NULL
might	NULL
sensitize	NULL
JNK	NULL
to	NULL
p56	NULL
``	NULL
**	NULL
independent	NULL
signals	NULL
involved	NULL
in	NULL
JNK	NULL
activation	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
,	NULL
anti-CD2	NULL
stimulation	NULL
is	NULL
accompanied	NULL
by	NULL
the	NULL
enhanced	NULL
binding	NULL
of	NULL
the	NULL
c-Jun/c-Fos	NULL
heterodimers	NULL
to	NULL
the	NULL
consensus	NULL
AP-1	NULL
sequence	NULL
leading	NULL
to	NULL
IL-2	NULL
production	NULL
.	NULL

A	NULL
previous	NULL
study	NULL
performed	NULL
by	NULL
stimulating	NULL
Jurkat	NULL
cells	NULL
with	NULL
superantigen	NULL
pulsed	NULL
HLA-DR	NULL
transfectants	NULL
revealed	NULL
differences	NULL
in	NULL
the	NULL
composition	NULL
of	NULL
the	NULL
NF-AT-AP-1	NULL
complexes	NULL
following	NULL
costimulation	NULL
with	NULL
either	NULL
--	NULL
~4e	NULL
@	NULL
__-	NULL
@	NULL
_	NULL
tan	NULL
Near	NULL
]	NULL
[	NULL
Ne	NULL
3	NULL
fossng	NULL
[	NULL
ara	NULL
]	NULL
[	NULL
oot	NULL
|	NULL
___	NULL
)	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
SIGNAL	NULL
TRANSDUCTION	NULL
VIA	NULL
CD2	NULL
CD2	NULL
CD2	NULL
ploy	NULL
ver	NULL
R	NULL
PIP	NULL
,	NULL
ZN	NULL
ca	NULL
pag	NULL
-	NULL
IPs	NULL
®GEEB£	NULL
|	NULL
}	NULL
®	NULL
Y	NULL
PKC	NULL
<	NULL
-	NULL
Cat	NULL
[	NULL
Be	NULL
]	NULL
+	NULL
CALMODULIN	NULL
}	NULL
caLciNEuRrIN	NULL
NFATP	NULL
x	NULL
``	NULL
JNK	NULL
NF-AT	NULL
SRE	NULL
|	NULL
[	NULL
nee	NULL
|	NULL
|	NULL
ar	NULL
net	NULL
IL-2	NULL
Promoter	NULL
__	NULL
*========	NULL
>	NULL
»	NULL
>	NULL
IL	NULL
'	NULL
2	NULL
LFA-3	NULL
or	NULL
B7	NULL
(	NULL
87	NULL
)	NULL
.	NULL

These	NULL
differences	NULL
were	NULL
due	NULL
to	NULL
the	NULL
dimerization	NULL
of	NULL
JunD	NULL
with	NULL
different	NULL
members	NULL
of	NULL
the	NULL
Fos	NULL
family	NULL
(	NULL
Fral	NULL
and	NULL
Fra2	NULL
)	NULL
,	NULL
indicating	NULL
a	NULL
selective	NULL
induction	NULL
of	NULL
certain	NULL
nuclear	NULL
factors	NULL
depending	NULL
on	NULL
the	NULL
costimulatory	NULL
pathway	NULL
.	NULL

In	NULL
our	NULL
current	NULL
study	NULL
,	NULL
we	NULL
observed	NULL
no	NULL
significant	NULL
difference	NULL
in	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
NF-AT	NULL
consensus	NULL
site	NULL
upon	NULL
anti-CD2	NULL
versus	NULL
anti-CD3	NULL
stimulated	NULL
JCaM1.6s.83	NULL
.	NULL

Since	NULL
the	NULL
MAPK	NULL
pathway	NULL
,	NULL
known	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
Fos	NULL
transcription	NULL
,	NULL
is	NULL
non-functional	NULL
in	NULL
JCaM1.6	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
Fral	NULL
and	NULL
Fra2	NULL
Fos	NULL
family	NULL
members	NULL
complexed	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
JCaM1.6s.83	NULL
is	NULL
perhaps	NULL
not	NULL
unexpected	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
coordinate	NULL
action	NULL
of	NULL
TCR	NULL
engagement	NULL
and	NULL
the	NULL
B7	NULL
versus	NULL
LFA-3	NULL
costimulatory	NULL
signal	NULL
could	NULL
differentially	NULL
induce	NULL
Fos	NULL
family	NULL
proteins	NULL
.	NULL

In	NULL
the	NULL
study	NULL
by	NULL
Parra	NULL
et	NULL
al	NULL
.	NULL

(	NULL
87	NULL
)	NULL
,	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
complexes	NULL
binding	NULL
to	NULL
their	NULL
respective	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
revealed	NULL
no	NULL
differences	NULL
after	NULL
either	NULL
type	NULL
of	NULL
costimulation	NULL
.	NULL

By	NULL
stimulation	NULL
via	NULL
CD2	NULL
alone	NULL
,	NULL
we	NULL
found	NULL
not	NULL
only	NULL
JunD	NULL
but	NULL
also	NULL
c-Jun	NULL
induced	NULL
and	NULL
heterodimerizing	NULL
with	NULL
c-Fos	NULL
in	NULL
JCaM1.6s.83	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

Since	NULL
the	NULL
AP-1	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
a	NULL
relatively	NULL
low	NULL
affinity	NULL
site	NULL
(	NULL
83	NULL
)	NULL
,	NULL
Fos-Jun	NULL
heterodimers	NULL
,	NULL
which	NULL
are	NULL
more	NULL
effective	NULL
in	NULL
DNA	NULL
binding	NULL
and	NULL
transactivation	NULL
(	NULL
55	NULL
)	NULL
,	NULL
might	NULL
be	NULL
required	NULL
for	NULL
optimal	NULL
activity	NULL
.	NULL

Additionally	NULL
,	NULL
c-Jun	NULL
and	NULL
c-Fos	NULL
in	NULL
contrast	NULL
to	NULL
JunB	NULL
,	NULL
Fral	NULL
,	NULL
and	NULL
Fra2	NULL
are	NULL
more	NULL
efficient	NULL
transactivators	NULL
(	NULL
55	NULL
,	NULL
88	NULL
,	NULL
89	NULL
)	NULL
.	NULL

The	NULL
function	NULL
of	NULL
JunD	NULL
in	NULL
IL-2	NULL
gene	NULL
transcription	NULL
is	NULL
not	NULL
defined	NULL
yet	NULL
.	NULL

Anergy	NULL
,	NULL
a	NULL
state	NULL
of	NULL
T	NULL
cell	NULL
unresponsiveness	NULL
to	NULL
antigenic	NULL
chal-lenge	NULL
,	NULL
which	NULL
is	NULL
induced	NULL
by	NULL
TCR	NULL
stimulation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
CD28	NULL
costimulatory	NULL
signal	NULL
(	NULL
90	NULL
)	NULL
,	NULL
is	NULL
accompanied	NULL
by	NULL
preferential	NULL
induction	NULL
of	NULL
the	NULL
inhibitory	NULL
p50-p50	NULL
NF-	NULL
«	NULL
B	NULL
homodimer	NULL
and	NULL
a	NULL
reduced	NULL
binding	NULL
of	NULL
AP-1	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
91	NULL
,	NULL
92	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
it	NULL
was	NULL
shown	NULL
in	NULL
an	NULL
alloreactive	NULL
system	NULL
that	NULL
alloantigen	NULL
stimulation	NULL
induced	NULL
T	NULL
cell	NULL
anergy	NULL
can	NULL
be	NULL
reversed	NULL
in	NULL
those	NULL
cells	NULL
after	NULL
culture	NULL
in	NULL
IL-2	NULL
for	NULL
7	NULL
days	NULL
only	NULL
by	NULL
costimulation	NULL
with	NULL
CD58	NULL
(	NULL
17	NULL
)	NULL
.	NULL

This	NULL
ability	NULL
of	NULL
CD2	NULL
stimulation	NULL
to	NULL
reverse	NULL
anergy	NULL
is	NULL
unique	NULL
and	NULL
distinct	NULL
from	NULL
costimulatory	NULL
molecules	NULL
such	NULL
as	NULL
CD28	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Our	NULL
observation	NULL
that	NULL
CD2	NULL
stimulation	NULL
can	NULL
activate	NULL
JNK	NULL
and	NULL
leads	NULL
to	NULL
the	NULL
induction	NULL
and	NULL
binding	NULL
of	NULL
c-Jun/	NULL
c-Fos	NULL
heterodimers	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
might	NULL
provide	NULL
a	NULL
basis	NULL
for	NULL
the	NULL
role	NULL
CD2	NULL
plays	NULL
in	NULL
regulating	NULL
anergy	NULL
.	NULL

This	NULL
possibly	NULL
remains	NULL
to	NULL
be	NULL
investigated	NULL
in	NULL
anergized	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
study	NULL
provide	NULL
evidence	NULL
for	NULL
a	NULL
CD2	NULL
signaling	NULL
pathway	NULL
distinct	NULL
from	NULL
that	NULL
of	NULL
the	NULL
TCR	NULL
and	NULL
capable	NULL
of	NULL
inducing	NULL
IL-2	NULL
production	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

This	NULL
CD2	NULL
stimulation	NULL
induced	NULL
signaling	NULL
cascade	NULL
does	NULL
not	NULL
involve	NULL
either	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
p56	NULL
``	NULL
-independent	NULL
CD2	NULL
Signaling	NULL
24257	NULL
p56	NULL
``	NULL
or	NULL
ZAP70	NULL
,	NULL
key	NULL
molecules	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
via	NULL
the	NULL
TCR	NULL
,	NULL
and	NULL
can	NULL
also	NULL
be	NULL
initiated	NULL
by	NULL
CD2	NULL
triggering	NULL
in	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

CD2	NULL
activates	NULL
Pyk2	NULL
and	NULL
undoubtedly	NULL
other	NULL
kinases	NULL
,	NULL
and	NULL
subsequently	NULL
stimulates	NULL
JNK	NULL
independent	NULL
of	NULL
p56	NULL
``	NULL
**	NULL
.	NULL

The	NULL
precise	NULL
definition	NULL
of	NULL
the	NULL
intermediate	NULL
steps	NULL
in	NULL
this	NULL
activation	NULL
cascade	NULL
will	NULL
now	NULL
be	NULL
of	NULL
interest	NULL
to	NULL
determine	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Drs	NULL
.	NULL

A.	NULL
Rao	NULL
and	NULL
T.	NULL
Roberts	NULL
for	NULL
careful	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Howard	NULL
,	NULL
F.	NULL
D.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Wong	NULL
,	NULL
J.	NULL
,	NULL
Bieber	NULL
,	NULL
C.	NULL
P.	NULL
,	NULL
Stinson	NULL
,	NULL
E.	NULL
B.	NULL
,	NULL
and	NULL
Herzenberg	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

126	NULL
,	NULL
2117-2122	NULL
2	NULL
.	NULL

Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Martin	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
Hansen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Brown	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Siadak	NULL
,	NULL
A.	NULL
W.	NULL
,	NULL
and	NULL
Nowinski	NULL
,	NULL
R.	NULL
C.	NULL
(	NULL
1981	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

152	NULL
,	NULL
207-212	NULL
3	NULL
.	NULL

Rodewald	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
Awad	NULL
,	NULL
K.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
D'Adamio	NULL
,	NULL
L.	NULL
,	NULL
Rabinowitz	NULL
,	NULL
D.	NULL
,	NULL
Shinkai	NULL
,	NULL
Y.	NULL
,	NULL
Alt	NULL
,	NULL
F.	NULL
W.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1998	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

177	NULL
,	NULL
1079-1092	NULL
4	NULL
.	NULL

Selvaraj	NULL
,	NULL
P.	NULL
,	NULL
Plunkett	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Dustin	NULL
,	NULL
M.	NULL
,	NULL
Sanders	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
Shaw	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Springer	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
826	NULL
,	NULL
400-403	NULL
5	NULL
.	NULL

Krensky	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Sanchez-Madrid	NULL
,	NULL
F.	NULL
,	NULL
Robbins	NULL
,	NULL
E.	NULL
,	NULL
Nagy	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Springer	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

181	NULL
,	NULL
611-616	NULL
.	NULL

Dustin	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
Springer	NULL
,	NULL
T.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
841	NULL
,	NULL
619-624	NULL
.	NULL

Moingeon	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
Lucich	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Stebbins	NULL
,	NULL
C.	NULL
C.	NULL
,	NULL
Recny	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Wallner	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
Koyasu	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21	NULL
,	NULL
605-610	NULL
8	NULL
.	NULL

Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Chang	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Sayre	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Clayton	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Alcover	NULL
,	NULL
A.	NULL
,	NULL
Gardner	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
19892	NULL
)	NULL
Immunol	NULL
.	NULL

Rev	NULL
.	NULL

111	NULL
,	NULL
111-144	NULL
9	NULL
.	NULL

Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Chang	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Wallner	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
Stebbins	NULL
,	NULL
C.	NULL
,	NULL
Frey	NULL
,	NULL
A	NULL
.	NULL

Z.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
889	NULL
,	NULL
312-314	NULL
10	NULL
.	NULL

Koyasu	NULL
,	NULL
S.	NULL
,	NULL
Lawton	NULL
,	NULL
T.	NULL
,	NULL
Novick	NULL
,	NULL
D.	NULL
,	NULL
Reeny	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Siliciano	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
Wallner	NULL
,	NULL
B.	NULL
P.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Nafl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

87	NULL
,	NULL
2603-2607	NULL
11	NULL
.	NULL

Meuer	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Hussey	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Fabbi	NULL
,	NULL
M.	NULL
,	NULL
Fox	NULL
,	NULL
D.	NULL
,	NULL
Acuto	NULL
,	NULL
O.	NULL
,	NULL
Fitzgerald	NULL
,	NULL
K.	NULL
A.	NULL
,	NULL
Hodgdon	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Protentis	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Schlossman	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1984	NULL
)	NULL
Cell	NULL
36	NULL
,	NULL
897-906	NULL
12	NULL
.	NULL

Brottier	NULL
,	NULL
P.	NULL
,	NULL
Boumsell	NULL
,	NULL
L.	NULL
,	NULL
Gelin	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Bernard	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

135	NULL
,	NULL
1624-1631	NULL
13	NULL
.	NULL

Siliciano	NULL
,	NULL
R.	NULL
F.	NULL
,	NULL
Pratt	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Schmidt	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Ritz	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1985	NULL
)	NULL
Nature	NULL
817	NULL
,	NULL
428-430	NULL
14	NULL
.	NULL

Li	NULL
,	NULL
J.	NULL
,	NULL
Smolyar	NULL
,	NULL
A.	NULL
,	NULL
Sunder-Plassmann	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

268	NULL
,	NULL
209-226	NULL
15	NULL
.	NULL

Gollob	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Li	NULL
,	NULL
J.	NULL
,	NULL
Kawasaki	NULL
,	NULL
H.	NULL
,	NULL
Daley	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Groves	NULL
,	NULL
C.	NULL
,	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
and	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
1886-1898	NULL
16	NULL
.	NULL

Gollob	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Li	NULL
,	NULL
J.	NULL
,	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
and	NULL
Ritz	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
,	NULL
T2l-731	NULL
17	NULL
.	NULL

Boussictis	NULL
,	NULL
V.	NULL
A.	NULL
,	NULL
Freeman	NULL
,	NULL
G.	NULL
J.	NULL
,	NULL
Griffin	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Gray	NULL
,	NULL
G.	NULL
S.	NULL
,	NULL
Gribben	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
and	NULL
Nadler	NULL
,	NULL
L.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
1665-1678	NULL
18	NULL
.	NULL

He	NULL
,	NULL
Q.	NULL
,	NULL
Beyers	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
Barclay	NULL
,	NULL
A.	NULL
N.	NULL
,	NULL
and	NULL
Williams	NULL
,	NULL
A.	NULL
F.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
54	NULL
,	NULL
979-984	NULL
19	NULL
.	NULL

Chang	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Lopez	NULL
,	NULL
P.	NULL
,	NULL
Krasnow	NULL
,	NULL
H.	NULL
,	NULL
Stebbins	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

169	NULL
,	NULL
2073-2083	NULL
20	NULL
.	NULL

Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Bogart	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
785-789	NULL
21	NULL
.	NULL

Brown	NULL
,	NULL
M.	NULL
H.	NULL
,	NULL
Sewell	NULL
,	NULL
W.	NULL
A.	NULL
,	NULL
Mason	NULL
,	NULL
D.	NULL
Y.	NULL
,	NULL
Rothbard	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Crumpton	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

18	NULL
,	NULL
12283-1227	NULL
22	NULL
.	NULL

Clayton	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Ramachandran	NULL
,	NULL
H.	NULL
,	NULL
Pravtcheva	NULL
,	NULL
D.	NULL
,	NULL
Chen	NULL
,	NULL
Y.	NULL
F.	NULL
,	NULL
Diamond	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Ruddle	NULL
,	NULL
F.	NULL
H.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

140	NULL
,	NULL
8617-3621	NULL
23	NULL
.	NULL

Pawson	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Gish	NULL
,	NULL
G.	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
359-362	NULL
24	NULL
.	NULL

Cohen	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
Ren	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Cell	NULL
80	NULL
,	NULL
237-248	NULL
25	NULL
.	NULL

Jin	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
Kaplan	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
White	NULL
,	NULL
M.	NULL
,	NULL
Spagnoli	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Roberts	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

144	NULL
,	NULL
647-652	NULL
26	NULL
.	NULL

Ley	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Davies	NULL
,	NULL
A	NULL
.	NULL

A.	NULL
,	NULL
Druker	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Crumpton	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

21	NULL
,	NULL
2208-2209	NULL
27	NULL
.	NULL

Howard	NULL
,	NULL
F.	NULL
D.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Moebius	NULL
,	NULL
U.	NULL
,	NULL
McConkey	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Yandava	NULL
,	NULL
B.	NULL
,	NULL
Gennert	NULL
,	NULL
T.	NULL
E.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176	NULL
,	NULL
139-145	NULL
28	NULL
.	NULL

Breitmeyer	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Daley	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Levine	NULL
,	NULL
H.	NULL
B.	NULL
,	NULL
and	NULL
Schlossman	NULL
,	NULL
S.	NULL
F.	NULL
(	NULL
1987	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

189	NULL
,	NULL
2899-2905	NULL
29	NULL
.	NULL

Alcover	NULL
,	NULL
A.	NULL
,	NULL
Alberini	NULL
,	NULL
C.	NULL
,	NULL
Acuto	NULL
,	NULL
O.	NULL
,	NULL
Clayton	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Transy	NULL
,	NULL
C.	NULL
,	NULL
Spagnoli	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Lopez	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1988	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

7	NULL
,	NULL
1973-1977	NULL
30	NULL
.	NULL

Bockenstedt	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
Goldsmith	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Dustin	NULL
,	NULL
M.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
Springer	NULL
,	NULL
T.	NULL
A.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

141	NULL
,	NULL
1904-1911	NULL
31	NULL
.	NULL

Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Lucich	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
McConkey	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Letourneur	NULL
,	NULL
F.	NULL
,	NULL
Malissen	NULL
,	NULL
B.	NULL
,	NULL
Kochan	NULL
,	NULL
J.	NULL
,	NULL
Chang	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Rodewald	NULL
,	NULL
H.	NULL
R.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1992	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

89	NULL
,	NULL
1492-1496	NULL
32	NULL
.	NULL

Arulanandam	NULL
,	NULL
A.	NULL
R.	NULL
N.	NULL
,	NULL
Koyasu	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

178	NULL
,	NULL
859-868	NULL
83	NULL
.	NULL

Chang	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Pedersen	NULL
,	NULL
R.	NULL
,	NULL
Lucich	NULL
,	NULL
J.	NULL
,	NULL
Stebbins	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172	NULL
,	NULL
851-355	NULL
34	NULL
.	NULL

Bell	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Fargnoli	NULL
,	NULL
J.	NULL
,	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
Kish	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

188	NULL
,	NULL
169-178	NULL
35	NULL
.	NULL

Gassmann	NULL
,	NULL
M.	NULL
,	NULL
Amrein	NULL
,	NULL
K.	NULL
E.	NULL
,	NULL
Flint	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Schraven	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
Burn	NULL
,	NULL
P.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24	NULL
,	NULL
189-144	NULL
36	NULL
.	NULL

Gupta	NULL
,	NULL
S.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
Kumar	NULL
,	NULL
G.	NULL
,	NULL
Wang	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Nel	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
17349-17357	NULL
37	NULL
.	NULL

Hunter	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
875-378	NULL
38	NULL
.	NULL

Su	NULL
,	NULL
B.	NULL
,	NULL
Jacinto	NULL
,	NULL
E.	NULL
,	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Kallunki	NULL
,	NULL
T.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Ben-Neriah	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
77	NULL
,	NULL
727-736	NULL
39	NULL
.	NULL

Tokiwa	NULL
,	NULL
G.	NULL
,	NULL
Dikic	NULL
,	NULL
I.	NULL
,	NULL
Lev	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Schlessinger	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
792-794	NULL
40	NULL
.	NULL

Quian	NULL
,	NULL
D.	NULL
,	NULL
Lev	NULL
,	NULL
S.	NULL
,	NULL
van-Oers	NULL
,	NULL
N.	NULL
S.	NULL
C.	NULL
,	NULL
Dikic	NULL
,	NULL
I.	NULL
,	NULL
Schlessinger	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

185	NULL
,	NULL
1258-1259	NULL
41	NULL
.	NULL

Weiss	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Daley	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
Hodgdon	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Naf	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
:	NULL
Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

14	NULL
,	NULL
259-274	NULL
57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

66	NULL
.	NULL

67	NULL
.	NULL

68	NULL
.	NULL

69	NULL
.	NULL

70	NULL
.	NULL

TL	NULL
.	NULL

72	NULL
.	NULL

73	NULL
.	NULL

74	NULL
.	NULL

75	NULL
.	NULL

76	NULL
.	NULL

77	NULL
.	NULL

78	NULL
.	NULL

79	NULL
.	NULL

80.	NULL
.	NULL

Muegge	NULL
,	NULL
K.	NULL
,	NULL
Williams	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Kant	NULL
,	NULL
J.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Schmidt	NULL
,	NULL
A.	NULL
,	NULL
82	NULL
.	NULL

83	NULL
.	NULL

84	NULL
.	NULL

85	NULL
.	NULL

86	NULL
.	NULL

87	NULL
.	NULL

88	NULL
.	NULL

89	NULL
.	NULL

90	NULL
.	NULL

91	NULL
.	NULL

92	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

81	NULL
,	NULL
6836-6840	NULL
Straus	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Cell	NULL
70	NULL
,	NULL
585-598	NULL
Koyasu	NULL
,	NULL
S.	NULL
,	NULL
Tse	NULL
,	NULL
A.	NULL
G.	NULL
D.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Hussey	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Mildonian	NULL
,	NULL
A.	NULL
,	NULL
Hannisian	NULL
,	NULL
J.	NULL
,	NULL
Clayton	NULL
,	NULL
L.	NULL
K.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

91	NULL
,	NULL
6693-6697	NULL
Alcover	NULL
,	NULL
A.	NULL
,	NULL
Weiss	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Daley	NULL
,	NULL
J.	NULL
F.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Naf	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

88	NULL
,	NULL
2614-2618	NULL
Berridge	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Irvine	NULL
,	NULL
R.	NULL
F.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
841	NULL
,	NULL
197-325	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Stobo	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

161	NULL
,	NULL
446	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Littman	NULL
,	NULL
D.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
263-274	NULL
Fischer	NULL
,	NULL
S.	NULL
,	NULL
Marie-Cardine	NULL
,	NULL
A.	NULL
,	NULL
Ramos-Morales	NULL
,	NULL
F.	NULL
,	NULL
Bougeret	NULL
,	NULL
C.	NULL
,	NULL
Soula	NULL
,	NULL
M.	NULL
,	NULL
Maridonneau-Parini	NULL
,	NULL
L	NULL
,	NULL
and	NULL
Benarous	NULL
,	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

40	NULL
,	NULL
605-609	NULL
Izquierdo	NULL
,	NULL
P.	NULL
M.	NULL
,	NULL
Reif	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Cantrell	NULL
,	NULL
D.	NULL
(	NULL
1995	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
16	NULL
,	NULL
159-164	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
855-361	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
129-157	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
A.	NULL
,	NULL
Smeal	NULL
,	NULL
T.	NULL
,	NULL
Minden	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
2135-2148	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Lob	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
383-8342	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
856	NULL
,	NULL
801-804	NULL
Ryseck	NULL
,	NULL
R.-P.	NULL
,	NULL
and	NULL
Bravo	NULL
,	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Oncogene	NULL
6	NULL
,	NULL
538-542	NULL
Crespo	NULL
,	NULL
P.	NULL
,	NULL
Bustelo	NULL
,	NULL
X.	NULL
R.	NULL
,	NULL
Aaronson	NULL
,	NULL
D.	NULL
S.	NULL
,	NULL
Coso	NULL
,	NULL
O	NULL
.	NULL

A.	NULL
,	NULL
Lopez-Barahona	NULL
,	NULL
M.	NULL
,	NULL
Barbacid	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Gutkind	NULL
,	NULL
J.	NULL
S.	NULL
(	NULL
1996	NULL
)	NULL
Oncogene	NULL
18	NULL
,	NULL
455-460	NULL
Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
,	NULL
Poggi	NULL
,	NULL
A.	NULL
,	NULL
Kozumbo	NULL
,	NULL
W.	NULL
J.	NULL
,	NULL
Moretta	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Moretta	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

17	NULL
,	NULL
55-60	NULL
Hubert	NULL
,	NULL
P.	NULL
,	NULL
Lang	NULL
,	NULL
V.	NULL
,	NULL
Debre	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Bismuth	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
4322-4332	NULL
King	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Sadra	NULL
,	NULL
A.	NULL
,	NULL
Han	NULL
,	NULL
A.	NULL
,	NULL
Liu	NULL
,	NULL
X.-R.	NULL
,	NULL
Sunder-Plassmann	NULL
,	NULL
R.	NULL
,	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
,	NULL
and	NULL
Dupont	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Int	NULL
.	NULL

Immunol	NULL
.	NULL

8	NULL
,	NULL
1707-1714	NULL
Bell	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Imboden	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
5548-5554	NULL
Anderson	NULL
,	NULL
S.	NULL
J.	NULL
,	NULL
Levin	NULL
,	NULL
S.	NULL
D.	NULL
,	NULL
and	NULL
Perlmutter	NULL
,	NULL
R.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Adv	NULL
.	NULL

Immunol	NULL
.	NULL

56	NULL
,	NULL
151-178	NULL
Molina	NULL
,	NULL
T.	NULL
J.	NULL
,	NULL
Kishira	NULL
,	NULL
K.	NULL
,	NULL
Siderovski	NULL
,	NULL
D.	NULL
P.	NULL
,	NULL
van-Ewijk	NULL
,	NULL
W.	NULL
,	NULL
Narendran	NULL
,	NULL
A.	NULL
,	NULL
Timms	NULL
,	NULL
E.	NULL
,	NULL
Wakeham	NULL
,	NULL
A.	NULL
,	NULL
Paige	NULL
,	NULL
C.	NULL
J.	NULL
,	NULL
Hartmann	NULL
,	NULL
K.-U	NULL
.	NULL

,	NULL
Veillette	NULL
,	NULL
A.	NULL
,	NULL
Davidson	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Mak	NULL
,	NULL
T.	NULL
W.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
857	NULL
,	NULL
161-164	NULL
Iwashima	NULL
,	NULL
M.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
van-Oers	NULL
,	NULL
N.	NULL
S.	NULL
C.	NULL
,	NULL
Chan	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Science	NULL
268	NULL
,	NULL
1186-1139	NULL
van-Oers	NULL
,	NULL
N.	NULL
S.	NULL
C.	NULL
,	NULL
Killeen	NULL
,	NULL
N.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183	NULL
,	NULL
1053-1062	NULL
Sunder-Plassmann	NULL
,	NULL
R.	NULL
,	NULL
Lialios	NULL
,	NULL
F.	NULL
,	NULL
Madsen	NULL
,	NULL
M.	NULL
,	NULL
Koyasu	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1997	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27	NULL
,	NULL
2001-2009	NULL
Burkhardt	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Stealey	NULL
,	NULL
B.	NULL
,	NULL
Rowley	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Mahajan	NULL
,	NULL
S.	NULL
,	NULL
Prendergast	NULL
,	NULL
M.	NULL
,	NULL
Fargnoli	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
23642-24647	NULL
Latour	NULL
,	NULL
S.	NULL
,	NULL
Chow	NULL
,	NULL
L.	NULL
M.	NULL
L.	NULL
,	NULL
and	NULL
Veillette	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
22782-22790	NULL
Fargnoli	NULL
,	NULL
J.	NULL
,	NULL
Burkhardt	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Laverty	NULL
,	NULL
M.	NULL
,	NULL
Kut	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
van-Oers	NULL
,	NULL
N.	NULL
S.	NULL
C.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Bolen	NULL
,	NULL
J	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
26533-26537	NULL
Wange	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
Samelson	NULL
,	NULL
L.	NULL
E.	NULL
(	NULL
1996	NULL
)	NULL
Immunity	NULL
5	NULL
,	NULL
197-205	NULL
Gelfand	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
Cheung	NULL
,	NULL
R.	NULL
K.	NULL
,	NULL
Mills	NULL
,	NULL
G.	NULL
B.	NULL
,	NULL
and	NULL
Grinstein	NULL
,	NULL
S.	NULL
(	NULL
1988	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

18	NULL
,	NULL
917-922	NULL
Gardner	NULL
,	NULL
P.	NULL
,	NULL
Alcover	NULL
,	NULL
A.	NULL
,	NULL
Kuno	NULL
,	NULL
M.	NULL
,	NULL
Moingeon	NULL
,	NULL
P.	NULL
,	NULL
Weyand	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
Goronzy	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Reinherz	NULL
,	NULL
E.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264	NULL
,	NULL
1068-1076	NULL
Goldsmith	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

84	NULL
,	NULL
6879-6883	NULL
Nishibe	NULL
,	NULL
S.	NULL
,	NULL
Wahl	NULL
,	NULL
M.	NULL
I.	NULL
,	NULL
Hernandez-Sotomayor	NULL
,	NULL
S.	NULL
M.	NULL
T.	NULL
,	NULL
Tonks	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
Rhee	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
and	NULL
Carpenter	NULL
,	NULL
G.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
250	NULL
,	NULL
1253-1256	NULL
Ramos-Morales	NULL
,	NULL
F.	NULL
,	NULL
Druker	NULL
,	NULL
B.	NULL
J.	NULL
,	NULL
and	NULL
Fischer	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Oncogene	NULL
9	NULL
,	NULL
1917-1928	NULL
Derjjard	NULL
,	NULL
B.	NULL
,	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Wu	NULL
,	NULL
I	NULL
.	NULL

-H.	NULL
,	NULL
Barrett	NULL
,	NULL
T.	NULL
,	NULL
Su	NULL
,	NULL
B.	NULL
,	NULL
Deng	NULL
,	NULL
T.	NULL
,	NULL
Karin	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Davis	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
76	NULL
,	NULL
1025-1037	NULL
Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
Shaw	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Bush	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Replogle	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Balgaje	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8	NULL
,	NULL
1715-1724	NULL
Kamps	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Corcoran	NULL
,	NULL
L.	NULL
,	NULL
LeBowitz	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

10	NULL
,	NULL
5464-5472	NULL
Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irvine	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313-316	NULL
Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Nolan	NULL
,	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

147	NULL
,	NULL
2734-2739	NULL
Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
and	NULL
Durum	NULL
,	NULL
S.	NULL
K.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
246	NULL
,	NULL
249-251	NULL
Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmaes	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
L.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
S.	NULL
,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

8	NULL
,	NULL
465-473	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

148	NULL
,	NULL
1240-1250	NULL
Ullman	NULL
,	NULL
K.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
(	NULL
1993	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

7	NULL
,	NULL
188-196	NULL
DeGrazia	NULL
,	NULL
U.	NULL
,	NULL
Felli	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Vacca	NULL
,	NULL
A.	NULL
,	NULL
Farina	NULL
,	NULL
A.	NULL
R.	NULL
,	NULL
Maroder	NULL
,	NULL
M.	NULL
,	NULL
Cappabianca	NULL
,	NULL
L.	NULL
,	NULL
Meco	NULL
,	NULL
D.	NULL
,	NULL
Farina	NULL
,	NULL
M.	NULL
,	NULL
Screpanti	NULL
,	NULL
L.	NULL
,	NULL
Frati	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Gulino	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

180	NULL
,	NULL
1485-1497	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Chen	NULL
,	NULL
L.	NULL
,	NULL
Thomas	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
869	NULL
,	NULL
497-502	NULL
Parra	NULL
,	NULL
E.	NULL
,	NULL
Varga	NULL
,	NULL
M.	NULL
,	NULL
Hedlund	NULL
,	NULL
G.	NULL
,	NULL
Kalland	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Dohlsten	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
1814-1828	NULL
Chiu	NULL
,	NULL
R.	NULL
,	NULL
Angel	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Karin	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Cell	NULL
59	NULL
,	NULL
979-986	NULL
Suzuki	NULL
,	NULL
T.	NULL
,	NULL
Okuno	NULL
,	NULL
H.	NULL
,	NULL
Yoshida	NULL
,	NULL
T.	NULL
,	NULL
Endo	NULL
,	NULL
T.	NULL
,	NULL
Nishina	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Iba	NULL
,	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19	NULL
,	NULL
5587-5542	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
(	NULL
1990	NULL
)	NULL
Science	NULL
248	NULL
,	NULL
1349-1356	NULL
Kang	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Bart	NULL
,	NULL
B.	NULL
,	NULL
Tran	NULL
,	NULL
A.	NULL
C.	NULL
,	NULL
Brorson	NULL
,	NULL
K.	NULL
,	NULL
Schwartz	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
and	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Science	NULL
257	NULL
,	NULL
1184-1138	NULL
Sundstedt	NULL
,	NULL
A.	NULL
,	NULL
Sigvardsson	NULL
,	NULL
M.	NULL
,	NULL
Leanderson	NULL
,	NULL
T.	NULL
,	NULL
Hedlund	NULL
,	NULL
G.	NULL
,	NULL
Kalland	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Dohlsten	NULL
,	NULL
M.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
979-984	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
A	NULL
p56	NULL
Ick	NULL
-independent	NULL
Pathway	NULL
of	NULL
CD2	NULL
Signaling	NULL
Involves	NULL
Jun	NULL
Kinase	NULL
Raute	NULL
Sunder-Plassmann	NULL
and	NULL
Ellis	NULL
L.	NULL
Reinherz	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1998	NULL
,	NULL
273:24249-24257.	NULL
doi	NULL
:	NULL
10.1074/jb0.273.37.24249	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/273/37/24249	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
92	NULL
references	NULL
,	NULL
50	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full.html	NULL
#	NULL
ref-list-1	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

